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ABSTRACT OF DISSERTATION

UNDERSTANDING THE IMPACT OF SOLVENTS IN ORAL SOLID DOSAGE
FORMULATION AND PROCESS DEVELOPMENT
The successful delivery of chemical compounds for the purpose of therapeutic
treatments and prophylactics is a substantial undertaking in modern drug development.
Notably, the adoption of high throughput screening techniques has led to the proliferation
of poorly water soluble and/or highly potent molecules which further complicate
development activities. Spray dried amorphous solid dispersions are an increasingly
important formulation strategy to overcome solubility issues while wet granulation
approaches are the method of choice for the preparation of highly potent APIs in oral solid
dosage forms.
A common connection between these critical techniques is their reliance on solventbased processing that can often result in unexpected outcomes on product quality and
performance. Solvent choice has been shown to influence API form, habit, stabilizing
interactions, and physical and chemical properties of drug product intermediates, which
requires greater understanding. The objective of this dissertation is to provide a general
overview and assessment of the role of solvents in the important methods of spray dried
dispersions (SDDs) and highly potent compounds by wet shear granulations (HP-WSG) to
address concerns related to poorly soluble and/or highly potent APIs.
Light scattering (LS) and dilute solution viscometry (DSV) techniques have been
utilized to assess critical drug-polymer-solvent interactions in the solution state and explore
the mechanisms by which solvent choice may influence SDD physical stability. Next, solidstate characterization techniques were leveraged to understand how the interplay between
wet granulation processing parameters, API physical form, and environmental moisture may
dictate chemical stability issues of a highly potent API. Conclusions and future work are
presented with next steps that can be pursued in expanding our knowledge of complex multicomponent solutions which are frequently encountered in pharmaceutical development.
KEYWORDS: spray dried dispersions, wet granulation, light scattering, rheometry,
solvent processing, drug product development
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CHAPTER 1: CHALLENGES IN MODERN DRUG PRODUCT DEVELOPMENT

1.1

Making Molecules into Medicine

The successful delivery of chemical compounds for the purpose of therapeutic treatments and prophylactics is a substantial undertaking in modern drug development.
In order to achieve the desired quality, safety, and efficacy of drug products, a variety
of critical objectives must be met - including sufficient chemical and physical stability, manufactureability, patient acceptance and compliance, and the satisfaction of
quality and regulatory requirements. The task of making molecules into medicines
requires an extensive understanding and marriage of the target bio-performance metrics, material properties of the drug and functional excipients, as well as the processes
by which these products are manufactured. Traditional approaches of simple drugin-capsule formulations have increasingly become the exception rather than the rule.
Development scientists are now expected to leverage an ever expanding toolbox of
fundamental chemistry and materials science knowledge, techniques, and instrumentation in the design of pharmaceutical dosage forms.
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Figure 1.1: A successful drug product must fall within the overlap of formulation
material properties, process capabilities, and performance requirements.
Notably, the adoption of high throughput screening techniques has led to the proliferation of poorly water soluble [1, 2, 3] and/or highly potent molecules [4, 5, 6, 7]
which further complicate development activities. Approximately 90% of new chemical entities in the drug candidate pipeline are estimated to meet the criteria of the
bio-pharmaceutical classification system (BCS) for poor aqueous solubility and/or
permeability (Class II & IV compounds) [8]. While 20-30% of solubility issues might
be addressed through screening for suitable salt forms or polymorphs [9], the majority
of these compounds will require more advanced approaches to improve bioavailability.
There are many enabling formulations techniques that can address these concerns,
including cyclodextrins, self-microemulsifying drug delivery systems (SMEDDs), liposomes, micelles, co-crystals, and more - though one of the most effective and flourishing strategies is that of amorphous solid dispersions (ASDs) [10]. The unique solid
state properties of ASDs provide enhanced dissolution rates, solubility, and permeability [11] which have made them an attractive option in the pursuit of increased
bioavailability for BCS class II and IV molecules.
The formulation of highly potent molecules bring its own concerns and risks with
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respect to ensuring product safety and efficacy. High potencies require much smaller
dosages compared to conventional drug products, with low dosage forms typically
considered to be those below 1 mg - though they may be as minor as 10-25 µg, as in the
examples of levothyroxine [12] or Vitamin D. In these cases, the amount of excipients
greatly exceeds that of the active pharmaceutical ingredient (API) which results in
drug concentrations as low as 0.01% (w/w). Such minute amounts of drug substance
can add substantial complexity to formulation and process development, including:
difficulty in ensuring content uniformity of both drug product intermediates (DPIs)
and dosage forms, low API recovery due to losses in manufacturing, and chemical
instability which may be attributable to a range of sources such as increased relative
surface exposure, physical transformations, and/or high ratios of excipient to drug
amounts that may increase the likelihood of incompatibility [7]. Additional obstacles
often present themselves in analytical development as it can be difficult to develop
robust methods for the characterization of trace drug substance, impurities, physical
form, and degradation products due to complexity in extraction from DPIs and dosage
forms, maintaining drug stability during sample preparation, and the need to enhance
method sensitivities [7].
In order to meet the challenges of these poorly water soluble and/or highly potent
molecules, specialized formulation, process, and analytical strategies are often utilized to ensure successful product development. Spray dry processing has emerged as
the leading processing method for the preparation of BCS class II/IV drugs as ASDs
at commercial scale. This technique allows for the production of stable drug intermediates with readily tunable properties to facilitate ease of downstream processing.
Wet shear granulation (WSG) is one of the oldest and best understood techniques
in industrial pharmacy [13] and is considered the process of choice for dosage forms
containing highly potent APIs (HP-API) [7]. This approach not only allows for the
precise control of particle properties to aid downstream processing, but also provides a mechanism to ensure the uniform distribution of trace amounts of HP-APIs
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throughout the formulation. Additionally, WSG helps to reduce worker exposure to
potentially toxic materials during production through the minimization of dust generation compared to alternatives such as dry granulation techniques [7]. While spray
drying and wet granulations are very distinct and disparate processes - one key aspect
that they share in common, is the need for solvents during processing.
Solvents are essential and ubiquitous materials in pharmaceutical development
and manufacturing practices, and are extensively utilized from early stage active
pharmaceutical ingredient (API) synthesis and purification, to mid-stage intermediate processing such as spray drying and wet granulation, and late stage tablet
coating processes. Generally, the role of solvents in mid-late stage processing has
been under investigated in the pharmaceutical community, though there has been a
growing awareness of the need to better understand their effects on both DPIs and
drug products as more complex molecules and manufacturing methods have become
more numerous. For example, solvent selection has been found to exhibit profound
influence on API form, physical and chemical stability, particle size, porosity, uniformity, density and friability, flowability, compressibility, and dissolution performance
of both SDD [14, 15, 16, 17, 18, 19, 20, 21, 22] and WSG [23, 24, 25, 7, 26, 27, 28, 29]
products. The major complication in the interrogation of solvents in SDD and WSG
formulation and processing is that these systems typically consist of several different
materials, making it difficult to parse the mechanisms and interactions which govern
product outcomes.
1.2

Spray Drying (SD)

Note: Much of this section is a modified reproduction of a portion of the paper by
Defrese et al. (2020) [30], reproduced with permission.
The invention of the spray dryer can be traced to Samuel Percy and US patent
US125406A, which was granted in 1872 [31]. While there have been many improvements to spray drying in the past 150 years, the fundamentals of this method have not
4

substantially changed. In brief, spray dry processing begins with the introduction of
a liquid feed containing dissolved solids into the primary drying chamber. This liquid
is then atomized into a fine spray of small droplets to provide a high surface area to
volume ratio to facilitate a majority of solvent removal on the order of microseconds
[32, 33]. Co-current hot process gas evaporates the carrier solvent which leads to
subsequent particle solidification as the spray dried product.
These solid particles are then separated from the process gas stream through the
use of gas-solid cyclone separator(s) which leverages differences in the centrifugal
force experienced between the solid particles and gas due to variances in material
densities. This effect causes the solids to separate from the gas stream and fall out the
bottom of the cylcone for collection as the finished product. A bag filter is generally
necessary after the cyclone(s) to collect residual ‘fine’ powders that are often prevalent
in spray dry processing and difficult to separate by centrifugal force alone. Often,
additional secondary drying of the collected product is required as significant amounts
of residual solvents will remain. The filtered process gas stream is then either vented
to the atmosphere (open-loop) or recirculated as needed to recover spent solvent and
reconditioning of the process gas stream for continuous processing (closed-loop).
Though this process appears fairly straightforward on the surface, there are many
process and formulation parameters that can exert substantial impact on the properties of the spray dried product that often requires extensive experimentation to
understand and control [32, 33, 34, 35, 36, 37].
Atomization
The atomization process is an important step in spray drying, as the droplets generated can directly influence critical properties of the finished particles including
size, shape, morphology, and uniformity [33, 38, 39]). There are four primary spray
technologies that are utilized in pharmaceutical spray drying: rotary disc atomizers,
pressure nozzles, bi-fluid (also known as pneumatic) nozzles, and ultrasonic nozzles.
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Regardless of the atomization apparatus, all are impacted by the liquid feed physical
properties (i.e. density, viscosity, surface tension, and solids concentration), though
performance sensitivity to these factors may differ greatly.

Figure 1.2: Schematic of a closed-loop spray drying process and equipment. Cyclone(s) may be used in series to help increase efficiency of particle separation and
yields of finer particulates, though most commonly only one cyclone is used.
Rotary disc and pressure nozzle atomizers are generally restricted to use in commercial scale equipment due to processing realities that make these styles poorly
suited for smaller instruments. Atomization via rotary discs is achieved by the introduction of a liquid feed to the center of a rapidly spinning disc at speeds in the range
of 5,000 - 60,000 RPM (tip speeds of 100-200 m/s), causing the liquid to flow outward
and breakup radially [40]. This necessitates the use of a large diameter chamber otherwise a substantial amount of product may be lost due to deposition on the side
walls of the equipment [41]. Rotary discs can produce a range of droplet sizes from
20-200 µm with a somewhat broad droplet distribution [42]. For pressure nozzles,
atomization is produced by the tangential introduction of the liquid feed under high
6

pressures (typically 180-220 bar, up to a maximum of 450 bar), which generates turbulence within the nozzle head before vertically exiting through a narrow orifice as
breakup begins due to capillary instability [40, 43]. Primary limitations of pressure
nozzles are that the minimum required liquid mass flow rates are in excess of 5 kg/hr,
which are incompatible with early stage development. Additionally, it is not possible
to independently adjust the droplet size without changing the liquid feed flow rates otherwise an alternate nozzle design is needed [39]. A key benefit of pressure nozzles
is that they are able to produce droplet sizes ranging from 30-200 µm with more narrow distributions than those produced by both rotary discs and pneumatic nozzles
[42].
At laboratory and pilot scales, bi-fluid and ultrasonic nozzles are the atomizers of
choice. Bi-fluid nozzles, whereby pressurized air causes the breakup of the liquid feed
into droplets, consist of two major configurations - external mixing nozzles which are
the most commonly utilized, and internal mixing nozzles. For external mixing nozzles
the air is introduced to the liquid feed after it has exited the nozzle, while for internal
mixing designs, the air and liquid mix prior to exiting the nozzle orifice. Internal
mixing nozzles have a more efficient atomization process which allows for a reduction
in the required gas-liquid flow ratios to produce a target droplet size. This allows
them to be better suited for greater throughput than the external mixing nozzles,
though they are comparably more sensitive to changes in feed viscosity [39]. Both
pneumatic styles are considered to be among the best options as they allow for simple
direct control of droplet size by adjustment of the air pressure independently of the
liquid feed [40]. However, these nozzles tend to produce both finer droplets (range
of 5-75 µm) with less uniform distributions which can negatively impact downstream
processing [39]. Ultrasonic nozzles leverage high frequency acoustic waves to produce
very narrow droplet size distributions in the range of 20-100 µm, where higher frequencies produce smaller droplets [40]. Regrettably, each ultrasonic nozzle is limited
to a single frequency which adds difficulty in exploring a wide range of droplet sizes

7

and in general have low throughput which currently restricts their use to small scales.
Evaporation & Particle Formation
As the atomization process completes and the fluid is converted to droplets, solvent
evaporation and the liquid-solid phase transformation begins to take place. In most
cases, except when spraying strong crystallizers, the evaporation rates are sufficiently
high to produce amorphous materials due to the rapid vitrification and loss of mobility as the solvent is removed. Regardless, the particle formation process is highly
complex and requires an understanding and control of the radial distribution of solution components within the drying droplet to ensure desired particle properties [33].
The radial composition during the drying process can be affected by a number of
phenomena, though the most frequently considered are that of the surfactant activity
of solutes [18, 44] and the Peclet effect, i.e. surface enrichment caused by the rapid reduction of the droplet radius with solvent evaporation occurring at rates much greater
than solutes can diffuse to the center of the droplet [38].
Of these, the Peclet effect or number (P ei ) for solute i, is most sensitive to the
evaporation process and is a function of the solvent evaporation rate (κ) relative to
the solute diffusivity (Di ) [33]:
P ei =

κ
8Di

(1.1)

Often the evaporation rate is approximated to be constant, which allows the lifetime of the droplet to be expressed as:
d2 (t) = d20 − κt

(1.2)

Where d2 (t) is the droplet surface area as a function of time, d20 the initial droplet
surface area, and t is the drying time of the droplet. A simple rearrangement can then
allow for an estimate of the required droplet drying time (τD ) by setting d2 (t) = 0
and solving for time:
τD =
8

d20
κ

(1.3)

Ideally, this value will be smaller than the residence time of the droplets in the dryer,
which is generally estimated from the volume of the drying chamber and process gas
flow rate, in order to ensure sufficiently low residual solvent content in the finished
particles [45]. With knowledge of the evaporation rate and solute diffusivity, the
extent of surface enrichment can be approximated with an accuracy of ± 1% by the
following:
Ei =

P ei P e2i
P e3i
cs,i
=1+
+
−
cm,i
5
100 4000

(1.4)

Where Ei is the surface concentration of i (cs,i ) relative to the average concentration in the droplet (cm,i ). Knowledge of solute diffusivities can either be measured
experimentally by methods such as dynamic light scattering, or modeled by appropriate methods [46]. Evaporation rates are primarily driven by the difference in solvent
partial pressure at the surface of the droplet (Ys ) at the equilibrium temperature (Te )
relative to the partial pressure in the processing gas (Y∞ ) and can be approximated
by the following expression:
κ = 8Dg

ρg
(Ys (Te ) − Y∞ )
ρl

(1.5)

Where Dg is the diffusivity of the solvent in the gas phase, while ρg and ρl are the gas
and liquid phase densities, respectively. This relationship is a good approximation as
long as the droplet temperatures are much lower than the boiling point of the solvent,
otherwise additional complexity will be introduced [33]. For a given feed solution, the
primary mechanisms to control enrichment and particle morphology via the Peclet
effect is by manipulation of evaporation rates through the adjustment of droplet size
and processing gas temperature. Generally, dense, solid particles can be achieved
with slower evaporation rates while light and hollow particles are formed at faster
evaporation rates as the solutes are kinetically enriched at the surface (figure 1.3)

9

Figure 1.3: Morphology of mono-disperse glyco-protein particles produced at drying
temperatures of 25, 50, and 125 °C, from left to right, corresponding to Peclet numbers
of 2.7, 5.6, and 16.8;Reproduced with permission from [33].
Key considerations across production scales are the difference in evaporation capacities and residence times due to the size of equipment. The process gas flow rates
control the relative rate of solvent that can be evaporated, assuming the same temperature and atomization conditions. Larger spray dryers are supported by larger
air handler systems in order to support greater product throughput. Additionally,
the larger drying chamber volumes relative to process gas flow rates can increase the
residence time to facilitate enhanced solvent removal, which is desirable to potentially reduce the need for, or extent of, secondary drying processes. At all scales,
common challenges include low yields arising from material deposition on the equipment sidewalls and/or insufficient solvent removal resulting in ‘sticky’ product at the
chamber outlet. An understanding of material glass transition temperatures, residual
solvent content, and target outlet temperatures are needed to prevent and control
these complications.
Solids Separation
After exiting the drying chamber, the process gas containing the solid particles will
then pass through a cyclone(s) and bag filter for removal and collection of the dried
product. There are relatively few cyclone designs, with the most common being that
of the Stairmand centrifugal cyclone with a geometrical ratio of the cone length to
diameter of 4:1 [45]. Electrostatic particle separators are an emerging technology
10

which collect the solids from laminar process gas flow using an electric field generated
along the side walls of the separator with high efficiencies ≥85 [47], though the fundamental operations are poorly understood and have not yet been scaled up to pilot
and commercial scale applications [45].
For the Stairmand design, the particles are separated by the larger centrifugal
forces experienced relative to the gas phase due to the presence of a vortex formed by
the process gas within the cyclone. The larger, denser particles are separated most
easily near the top of the cyclone and will fall out of the vortex along the boundary
wall into the collection vessel due to gravity. Smaller, lighter particles are more likely
to be retained within the vortex and will not separate until lower in the cyclone where
the gas speeds are greater; or if sufficiently small, these fine particulates may stay
entrained and exit the cylcone in the gas stream for separation at later stages (i.e.
cyclone(s) &/or bag filters in series) or represent loss in yield for the remaining solids
which are irrecoverable. An understanding of the separation process is necessary
to ensure adequate yields which can be particularly important at laboratory and
pilot scales where smaller size particles are often generated and result in reduced
separation efficiencies. Differences in separation efficiency across scale can also cause
varying product characteristics, as different ranges of the particle distribution may
be collected based on cyclone designs and process conditions - even when the same
particle distribution is able to be produced at all scales. The key parameters for
cyclone performance are the pressure drop (∆Pt ) across the cyclone inlet and outlet
(as captured by Euler’s (Eu) number), and the collection efficiency (η) which is a
function of the process gas properties (as captured by Reynold’s (Re) number), and
particle properties (as captured by Stokes’ (St) number) [45]:




Re = ρgµνgi di




∆Pt
,
η = f (Re, St), where
Eu =

0.5ρg νi2



2

g )dp νi

St = (ρp −ρ
18µg d
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(1.6)

Where ρg is the gas density, νi the inlet gas velocity, di the cyclone inlet diameter,
µg the gas dynamic viscosity, ρp the mean particle density, dp the mean size particle
diameter, and d the cyclone diameter. In general, increasing the Stokes’ number
up to 0.01 by reducing the cyclone diameter can improve efficiency while a more
complex, process specific and non-linear relationship exists with respect to Re[45].
Optimization of solids separation and cyclone efficiency for spray dry processing is a
growing area of interest. Recent work by Poozesh et al. includes the design of a multibin centrifugal cyclone for improved collection efficiency as well as partitioning the
collected product by size according to the cyclone bins [48]. This valuable contribution
provides the means to partition product by size during the powder collection event
to allow for a better understanding of the drying and separation processes as a whole
in support of continued improvement of spray drying processes.

Figure 1.4: Two cyclones utilized in spray dry processing for the separation of particles from the processing gas steam. Left: Stairnmand or Vortex Cyclone; Right:
Electrostatic Separator. Reproduced with permission from [45]
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Secondary Drying
Secondary drying processes are usually required post spray drying due to relatively
high residual solvents content. Residual solvent content is limited for safety and environmental reasons per International Council for Harmonization (ICH) guidance for
industry Q3C Impurities: Residual Solvents with guidelines established for class
1, 2, and 3 solvents respectively. Class 1 solvents should be avoided at all costs in
the pharmaceutical industry due to a high degree of toxicity and/or environmental
hazard concerns. Class 2 solvents encompass those organic solvents which are suitable for use but should be limited when possible and must be carefully controlled
and reduced to acceptable limits in the final drug product. For spray drying applications methanol, tetrahydrofuran (THF), and dichloromethane (DCM) are the
class 2 solvents of greatest interest, with permitted daily exposure (PDE) limits of
30.0, 7.2, and 6.0 mg/day (or product concentrations of 3,000, 720, and 600 ppm),
respectively. Lastly, there are the class 3 solvents which exhibit less toxicity with
lower risks to human health such that no hazards are expected to be present from
typical levels found in pharmaceuticals. These solvents should be limited by GMP
or other quality-based requirements to PDE limits of 50 mg/day (corresponding to
5,000 ppm / 0.5% w/w) with additional strong justification should these targets not
be realistically achievable. The solvents most applicable to spray drying in this class
include acetone, most short chain alcohols (excluding methanol), acetic acid, methyl
and ethyl acetates [34]. Water is also frequently utilized, especially in mixtures with
miscible solvents to achieve the desired solubility of formulation excipients and API
for spray drying efficiency and control of desired particle properties [34].
Spray dried powders tend to retain residual solvents of approximately 1-10 % w/w
which necessitates additional solvent removal through a secondary drying process.
Vacuum tray and fluid bed drying are the most common methods to reduce solvent
content to acceptable levels. Notably, as novel APIs are increasingly poorly soluble
‘grease-balls’ or ‘rocks;’ stronger solvents may often be required for spray drying. As a
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consequence, residual solvents may have very low acceptable limits per ICH guidelines
and the secondary drying process may require exceedingly long times in tray drying
or risk excess exposure of thermally labile products to heat in fluid bed granulation to
reach target levels. Humid and/or solvent-assisted drying is a growing area of interest
to address these complications. In assisted drying techniques, process gas is fed to
the drying unit with varying levels of humidity and/or assisting solvent (typically
methanol) to help remove less desirable residual solvents. The mechanism behind
this approach is due to the plasticization effect that residual solvents have on glassy
materials that are produced by spray dry processing - this plasticity increase the
mobility and free volume of these materials which likewise increases the diffusion rate
of the residual solvent, allowing it to more rapidly escape the particles in comparison
to dry air or vacuum [49].
1.3

Spray Dried Dispersions (SDDs)

This section is a modified reproduction of a portion of the paper by Defrese et al.
(2020) [30], reproduced with permission.

Figure 1.5: The increasing utilization of ASDs in FDA approved drug products in
recent years. Reproduced with permission from [10]
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As can be seen by the striking growth of FDA approved products since the turn
of the century in figure 1.5, ASDs have become one of the most important and widely
employed formulation strategies to address the insufficient bio-availability of poorly
water soluble compounds [10]. They are manufactured by either melt or solvent-based
techniques [35] to create uniform intimate mixtures between the drug and polymer.
Of the various methods, spray drying is among the most popular at commercial scale
owing to its economic feasibility, compatibility with thermally labile materials, and its
ability to readily control desirable product attributes such as particle size, porosity,
and wettability in comparison to alternatives such as hot melt extrusion [35]. In
their simplest presentation, ASD intermediates typically consist of an amorphous
drug incorporated into a homogeneous single-phase molecular dispersion within a
polymeric carrier. In SDDs, this amorphous form is generated due to the rapid
removal of solvent which preserves the isotropic disordered packing of the liquid state
due to the loss of mobility from exponentially increasing viscosity experienced by the
drug and polymer during the drying process as the glass transition temperature is
approached. This produces a high energy metastable glassy state which increases the
drug solubility 2-70 fold [11] relative to the crystal form by reduction of the energy
barrier to dissolution through disruption of the crystal lattice [50, 51, 52].
Thermal History in Glasses
Notably, glasses are kinetically sensitive materials which are known to retain a ‘thermal history’ as the preserved molecular structure mirrors that of the starting conditions of the quench or drying process, with the glassy material exhibiting more similar
characteristics of the liquid state as the quench rate is increased [53]. This can be understood with an enthalpy-temperature diagram demonstrating the potential glassy
phase behaviors of an otherwise stable crystalline molecule at varying quench rates or
exposure to annealing temperatures per figure 1.6a. At sufficiently rapid quenching
rates, a liquid is unable to successfully re-orient its molecular packing to allow for
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crystallization prior to the onset of vitrification as the glass transition temperature
is approached. The quench rate reflects the initial disorder of the liquid state, where
faster rates form amorphous phases that are less dense and more disordered (glass 1),
whereas slower rates allow greater time for reorganization and densification resulting
in a lower energy form (glass 2). This kinetic sensitivity is a key point - it suggests
that the molecular interactions present in the solution and/or molten states must be
closely related to those retained in the solid-state - and they are most similar for those
conditions which provide the most rapid of vitrification processes. This has important and practical applications in understanding how solution state interactions may
be tunable for the optimization of SDD properties, which will be explored in later
chapters.

(a) Enthalpy-Temperature Diagram with glass
transformations, reproduced with permission from [53]

(b) Transmission Electron Microscope image of
crystal/glass interface of Si3 N4 , reproduced with
permission from [54]

Figure 1.6: Glass transformation & isotropic orientations relative to crystalline form
A natural consequence of producing kinetically restricted glassy materials is that
ASDs are inherently in a non-equilibrium state which is undergoing constant relaxations and sampling of the local energy landscape to minimize free energy [55]. Due to
the high energy state and chemical potential of the dispersed API, there often exists a
thermodynamic driving force for phase separation and/or re-crystallization which can
be prevented through sufficient mobility constraints and drug-polymer interactions in
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the solid-state [56, 57, 58]. The suppression of these transitions in ASD products
has been shown to be critical to the preservation of the desired stability, dissolution,
and efficacy performance [59, 60, 61, 62]. Therefore, it is essential to understand
and optimize the formation and maintenance of stabilizing drug-polymer interactions
throughout the thermal and processing history experienced by these materials.
Impact of Solvents on SDD properties
The impact of solvent choice in SDDs has garnered increasing attention regarding its
potential to influence key formulation properties such as homogeneity, physical stability, and dissolution performance [14, 15, 16, 18, 17, 63, 20, 21, 22, 44, 64, 65, 66].
Several rationalizations have been offered to explain solvent effects in SDDs which
include changes in droplet size, kinetic effects arising from varying evaporation rates,
and thermodynamic processes attributed to drug-polymer-solvent interactions prior
to and during the drying event. For common bi-fluid nozzles, droplet size is chiefly
determined by the physical properties of the liquid feed (e.g. viscosity, surface tension, and density), the atomizing gas to liquid mass flow rate ratios, and the nozzle
size and/or design [67]. As such, any change in solvent will impact dissolution performance due to alterations in the droplet (particle) size when otherwise holding the
remaining process parameters constant. This underscores the importance of conducting intrinsic dissolution studies to control for surface area when investigating solvent
effects exclusive of their impacts on the atomization process.
Furthermore, different solvents will exhibit a range of volatility and phase behavior
with drug and polymer solutes [22]. This can impact the evaporation rate as well as
dictate exposure to regions of immiscibility, such as spinodal envelopes (i.e. the onset
of spontaneous phase separation), that may be experienced during the solvent removal
process. The rate of phase separation in the spinodal region is typically understood
to be controlled by a combination of diffusivity and solute chemical potentials per
the Cahn-Hilliard equation [68, 69]. This introduces a complex kinetic and thermo-
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dynamic interaction that may present under varying solvent compositions, even after
controlling for droplet size and evaporation rate effects. For example, slower evaporation rates have been shown by Purohit et al. (2017) to reduce homogeneity for
systems that undergo phase separation during solvent removal [20].
Surface enrichment of either the drug or polymer has also been observed in SDDs.
Enrichment of the polymer is generally attributed to a kinetic process via the Peclet
effect [32, 33] which arises from dissimilarities in cosolute diffusion rates due to large
differences in molecular weights of the drug and polymer. During the evaporation
process, these differential diffusion rates result in a radial composition gradient within
the dried particle, as the polymer diffuses much more slowly than the drug and builds
up at the surface as the droplet collapses [38]. In contrast, the accumulation of
drug has been shown to be due to surfactant-like behavior of dissolved drug, which
rapidly migrates to the droplet surface after atomization and prior to completion
of the evaporation event [18, 44]. Lastly, and the area of focus in later chapters of
this work, initial solution-state drug-polymer interactions have also been proposed as
additional drivers of SDD homogeneity and stability.
Polymers in solution demonstrate a variety of complex phenomena that change in
response to their relative affinity for the solvent and cosolutes. Polymer conformation
can expand or contract in the presence of good or poor solvent interactions, as the
polymer adjusts to either swell and maximize its interactions with its environment
or instead collapse and interact preferentially with itself. When applied to SDDs, it
has been inferred that those conditions which produce an extended coil conformation
allow for greater opportunity for stabilizing drug-polymer contacts to form, relative
to the collapsed globular state [14, 15, 21]. Similarly, the presence of more elaborate
solution-state polymer-drug assemblies in the liquid feed was found to be correlated
with variations in SDD dissolution [63].
Dynamic light scattering (DLS) and dilute solution viscometry (DSV) are common techniques used to assess these conformational and structural changes, as char-
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acterized by hydrodynamic and viscometric diameters and particle-particle interactions in solution. However, such studies must be cautiously executed to ensure
accurate and reproducible results, especially for the selection of the appropriate
data analysis/treatment, concentration regime, sample purity, and method suitability
[70, 71, 72, 73, 74]. Our review of the existing SDD literature has found that such
considerations in previous studies have been poorly examined and warrant further
scrutiny.
Macromolecular solutions are biphasic systems consisting of the pervaded volume
of the macromolecule and the bulk solution [75]. Multi-component macromolecular
solutions exhibit preferential solvation behavior, whereby cosolvents/solutes with favorable net interactions tend to be sorbed within the local environment of the macromolecule, while those that are unfavorable will be excluded [76]. SDD liquid feeds
contain a minimum of three components (drug, polymer, solvent) and often more
- as cosolvents and/or formulation adjuvants are increasingly employed to address
solubility, processability, performance, safety, and environmental concerns [34]. The
relative affinity to or repulsion of drug cosolutes from the pervaded volume of the
polymer may play a significant role in the formation of stabilizing drug-polymer contacts that are necessary to preserve the amorphous character in the finished product.
It should be noted that this argument relies on the maintenance of these interactions
throughout the spray drying process, though this seems reasonable as such outcomes
were observed for the solution-state assemblies investigated by Dalsin et al [63]. As
the importance of cosolute preferential solvation/adsorption in protein formulation
stability has already been well established [77, 78], it is proposed that the solutionstate organization of spray drying liquid feeds will be likewise influential to successful
SDD development. These questions are further explored in chapters 2 and 3.
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1.4

Wet Granulation (WG)

Wet granulation approaches are among the oldest of particle engineering techniques
utilized in the manufacture of pharmaceutical tablets [7]; of which high shear wet
granulation (HSWG) is the most extensively employed in modern drug development
[79]. It is one of the many methods used to combine a variety of powdered formulation
materials through the agglomeration of smaller, primary particles with a liquid solvent and/or binder into larger units known as granules. These granules must exhibit
suitable flowability, density, and compressibility for use in high speed tableting processes [79]. Modern tableting equipment requires free flowing product that is able to
flow into and fill a small die cavity uniformly by volume at time scales on the order of
single microseconds [80]. Often, API powders consist of sub 50 µm, cohesive particles
with low density and poor or nonexistent flowability. High dose APIs will typically
form the bulk of the tablet formulation (i.e. ibuprofen and acetaminophen), which
means intermediate processing techniques such as granulation are needed to enhance
flowability and compressibility of the API to ensure a successful tablet can be produced [79]. In addition to flow and compressibility, granulations also serve to improve
content uniformity, reduce segregation through the generation of narrow particle size
distributions, improve tablet strength due to incorporation of binder excipients in
the granules, increase powder density, reduce dusting, and improve dissolution of the
drug product [7].
The HSWG process typically begins with the preparation of a well-mixed powder
bed, either by blending before granulation or more commonly, by mixing directly in
the granulation bowl prior to adding the granulating fluid. Liquid binder and/or wetting agents are often dissolved in a granulating solvent; this solution is then atomized
into droplets onto the powder bed, which is being simultaneously mixed with a large
spinning impeller at 100-500 RPM and granulated/densified with a small rapidly spinning chopping blade operatin in the range of 1000-3000 RPM [7]. This mixing and
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chopping facilitates distribution of the binder/cosolutes and generates a ‘wet mass’
product. Once all of the liquid solution has been added the process continues to mix
and chop until the granulation end point is reached. The granulation will then often
be wet milled and dried in a fluid bed dryer until the target residual solvent or moisture content is achieved [7]. Low shear wet granulation (LSWG) processes are similar
in concept and execution to HSWG, though instead the granulation is achieved using
a single low-speed mixing blade, often resulting in less dense, uniform, and robust
granules [81]. LSWG also tends to require 30-40 % more liquid binder relative to
HSWG to achieve comparable granules [7]. The types of processes which have been
determined to be fundamental in understanding wet granulation performance consist
of (1) wetting and nucleation, (2) consolidation and coalescence, and (3) breakage
and attrition [82] (figure 1.7).

Figure 1.7: Schematic of key wet granulation processes which dictate granule properties. Reproduced with permission from [82]
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Wetting and Nucleation
The process of wetting and nucleation is the act of bringing the liquid solution into
contact with the dry powder bed through which nuclei granules are formed due to the
liquid and powder interactions [82]. The atomization of the liquid feed is a critical
step in the wet granulation process as it can impact the granule size and uniformity
due to the droplet size distribution and spray pattern generated [83]. The initiation of
granule formation is typically understood via the ‘immersion nucleation’ mechanism
whereby the atomized droplets are much larger in size than the powder materials
such that the liquid binder permeates through the powder bed via capillary actions
to bind the loose particles together as the starting granule [83]. The key parameters
in understanding and scaling up this stage of the granulation process are the droplet
penetration time and the dimensionless spray flux. The droplet penetration time (tp )
into a loosely packed powder bed is a complex relationship dependent on the chemical
and physical properties of the liquid solution, the granulation powder bed, and their
relative affinity [83]:
2/3

tp = 1.35

µ
Vd
2
ef f Ref f γcosθ

(1.7)

Where Vd is the volume of the droplet size, ef f and Ref f are the effective bed voidage
and average pore size available for capillary flow, µ and γ are the liquid binder viscosity
and surface tension, and θ is the contact angle formed between the liquid binder
solution and the surface of the granulation bed. Of these properties, µ generally has
the greatest effect on granule properties as the liquid viscosity can easily vary within
several orders of magnitude depending on the solids concentration and/or binder
material that is used [83]. From the perspective of the powder properties, reducing
the initial powder particle size increases the penetration time due to reduced packing
efficiencies reflected in ef f and Ref f . In the case of very fine and cohesive powders,
equation 1.7 becomes less accurate and experimental tests are instead recommended
to support scale up activities [83]. The droplet penetration process can be visualized
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in figure ().

Figure 1.8: Water droplet penetrating into lactose powder at (a) impact; (b) 0.23s;
(c) 0.9s; (d) 1.4s; and (e) 2.3s. Reproduced with permission from [83]
The dimensionless spray flux (Ψa ) is defined as “the ratio of the rate at which
wetted area (ȧ) is created by the incoming droplets compared to the total area of dry
powder (Ȧ) passing through the spray zone" and is a measure of the density of the
liquid droplets striking the powder bed [83]:
P sia =

3V̇
ȧ
=
Ȧ
2Ȧdd

(1.8)

Ȧ may also be considered as the dynamic spray zone, which is a function of not
just the area of the spray pattern generated from the atomization process, but also
incorporates the rate of mixing and surface turnover of the powder bed. As the
powder mixing rate increases while holding the atomization process constant, then
Ψa will decrease as the fraction of the total powder bed area covered (fc overed) by the
liquid droplets reduces. If instead one holds the powder mixing rate constant while
increasing the liquid mass flow rate, then Ψa will increase as a greater proportion of
the powder surface is wetted. At values of Ψa ≤ 0.01, most of the spray droplets are
expected to form individual granules that reflect the droplet size distribution.
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Figure 1.9: Monte-Carlo simulation of spray flux. Reproduced with permission from
[83]
However, as Ψa increases, the droplets will begin to overlap and coalesce together
at the surface of the powder bed, eventually forming an almost continuous sheet of
liquid in the spray zone (figure 1.9). As the powder is moved and dispersed due to
the rotations of the impeller and chopper blades, the sheeting of liquid is mechanically dispersed into the powder bed and where it can bind with other particles or
droplet regimes to form a nucleus; rather than being formed purely due to the spray
droplet penetration process. The relative extent of this effect can be explored with
the dimensionless ratio (τp ) of the droplet penetration time to the powder circulation
time (tc ) back into the spray zone [83]:
τp =

tp
tc

(1.9)

Mechanical dispersion processes dominate under conditions of slow droplet penetration, fast powder re-circulation, and high spray flux (τp , Ψa ≥ 1)); while droplet nucleation dominates under the opposing conditions (τp , Ψa ≤ 0.1)), with intermediate
regimes consisting of substantial activity from both nucleation mechanisms between
these ranges (see figure 1.10). Droplet nucleation will tend to produce more uniform
granule distributions proportional to the droplet size distributions from the atomization process, while mechanical dispersion will be more broad. More often than not,
most granulators will operate within the mechanical dispersion regime due to both
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slow penetration times and rapid re-circulation times resulting in the agglomeration
of wet liquid regions [83].

Figure 1.10: Nucleation mechanism regime map as a function of τp and Ψa , with
droplet controlled dominating in the bottom left region, mechanical dispersion in the
upper right regions, and between a intermediate region where both mechanisms are
active. Reproduced with permission from [83]

Consolidation and Coalescence
The processes of granule consolidation and coalescence are the result of collisions
between granules, granules and the powder bed, or the granules and the equipment
which results in densification and growth [82] - as long as the binder solution is still
liquid; once dried, consolidation is no longer possible and instead attrition will occur
[83]. The granules first formed in the nucleation process are generally smaller with
low density and significant volumes of void space which results in weak granules that
are not appropriate for downstream processing. During the granulation process, the
granules grow and increase in size over time as dry particles adhere to wet granules (layering [82]) and/or wet granules agglomerate to one another (coalescence [82])
with increasing liquid addition. As these granules are exposed to shear forces caused
by the impeller and chopper blades, the granules are compressed and densified, resulting in less porous and stronger granules [83]. Should densification continue too
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far, the majority of the void space will be removed with increasing compaction such
that the relative saturation of the granules increases until the liquid fills all internal
voids and is then squeezed to the outer surface of the granule. This effect results in
rapid coalescence of granules such that a run away growth of granule size is observed
which is characteristic of the onset of induction granule growth behavior and/or ‘overgranulation’ [83] which correlates with a broader granule size distribution and poor
compactibility. An additional consequence of the lack of sufficient porosity can lead
to difficulties in dispersion and dissolution due to the loss of available surface area to
facilitate adequate release of an API [82].
Attrition and Breakage
The process of granule attrition and breakage is due to the fracture of ‘wet’ granules
attributed to impact, wear, and compaction in high shear wet granulation equipment
or in later product handling and downstream processing of ‘dry’ granules [82]. Notably, the mechanisms which govern the breakage and attrition of wet granules differs
substantially from dry granules such that they must be addressed separately. For wet
granules, deformation typically exhibits either plastic or semi-brittle behavior and is
only considered significant within high shear granulation processes (i.e. not LSWG or
fluid bed granulations) [83]. Plastic deforming wet granules are damaged due to the
extensive shear and extensional flow experienced in the granulator which can often be
confirmed due to the presence of smeared granules along the granulator walls or the
development of a paste instead of granules [82]. In contrast, semi-brittle behavior is
attributed to crack propagation initiated by impacts within the impeller zone and is
more likely to be observed for non-spherical granules [83]. Increases in impeller speeds
have been shown to consistently reduce granule size distributions attributed to brittle
breakage in HSWG processes, such that the larger granules are expected to be broken
preferentially to smaller granules [82]. The breakdown of granule properties are associated with the onset of over-granulation which is often monitored by tracking the
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the rapid loss in power consumption over the course of the wet granulation process
(figure 1.11) [79].

Figure 1.11: Power consumption profile of a high shear wet granulation process. Onset
of over-granulation indicated by rapid loss in power consumption. Reproduced with
permission from [79]
Attrition and breakage in dry granules is less well understood, though they are
known to fail in a brittle or semi-brittle fashion ascribed to a complex crack propagation process. The robustness of dry granules has been successfully correlated with
empirical three-point bend tests which are conducted by first forming solid bars of
out of wet granules with notches of known size, letting them dry fully and measuring
the force displacement required to fracture the bars [82]. The two primary proposed
mechanisms for dry granule breakage are fragmentation and wear or attrition. Fragmentation typically occurs when the size of the initial crack propagation site, or
process zone, is small relative to the granule size; this leads to the fracture of the
granule into multiple large pieces. In contrast, the attrition mechanism occurs when
the process zone size is on the order of the size of the granule and instead fine dust
is generated due to diffuse micro-cracking [82].
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Post Wet Granulation Processes
After completion of the wet shear granulation, multiple additional steps are generally
employed to prepare the drug product intermediate for further downstream processing
activities. The first step is wet milling or screening, where the still wet granulation is
passed through a screen of specific size to break down the largest granules to ensure
a more uniform size distribution with faster drying kinetics to minimize thermal
exposure of the granulation [7]. Wet milling may not always be necessary and is
typically dependent on the quality of the prepared granulation. Removal of residual
liquid from the granules is accomplished most often by either fluid bed or vacuum tray
dryers, similar to those discussed previously in the spray dry processing discussion in
section 1.2.4. Moisture content is an important parameter as it can have significant
impact on compactibility in tablet compression processes [7]. Lastly, dry milling or
sizing is performed after drying using conical screening and hammer mills to reduce
and control the final granule size distribution [7].
1.5

Wet Granulation of Highly Potent APIs (HP-APIs)

The primary benefits in the processing of HP-APIs by wet granulation is to ensure
content uniformity (CU) of the drug compound within the formulation as well as the
preparation of particles with acceptable flow and/or compression properties suitable
for downstream processing [82, 7, 83]. An additional goal is the reduction of ‘dusting,’
i.e. the ability for formulation materials to become easily airborne, which adds risks
to worker health due to the high potency nature of the APIs [7]. Densification and
particle agglomeration minimizes the risk of powder inhalation by preventing the
generation of airborne particles during handling and processing of the formulation
materials.
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Content Uniformity
As HP-APIs are typically in the range of 0.01-1 w/w% of the final formulation, it
may often be difficult to mitigate the many potential causes of heterogeneity and/or
potency loss. While its is commonly appreciated that the API tends to reside preferentially in the smallest particle class size (i.e ’fines’) both before and after granulation
due to small initial API particle size and resulting segregation [84, 85, 86], this can
still be a concern even when the API is previously prepared with a larger particle size
prior to granulation for the purpose of reducing this risk [87]. Another cause of granule heterogeneity has been shown to be due to differences in the wetting properties of
the excipient and API powders, such that the liquid binder interacts favorably with
the excipients which will form larger granules while the API may be repelled or settle
at the bottom of the granulation bowl to avoid the solvent [85]. This is expected
to be particularly relevant when the liquid binder solvent is water and the API is a
poorly water soluble compound resulting in limited API wettability. Extending the
wet massing granulation time has been shown to improve CU [86], though this may
not always be an acceptable solution as the granule physical properties are sensitive
to granulation time and there is an increased risk for the onset of over-granulation as
time increases [83].
A common technique to mitigate CU issues with HP-APIs is to incorporate the
drug compound into the liquid binder solution to facilitate the distribution of the
API onto the granule bed more evenly [88, 89]. This requires adequate atomization
of the liquid solution to ensure uniform dissemination, where slower liquid flow rates,
with narrow droplet size distributions and a broad spray zone would be preferred.
Notably, the properties of the atomization plume and liquid addition rate also affect the granule properties per the previous discussion, which must be taken into
consideration. However, this approach is not without its downsides as well. When
water is utilized as the liquid solvent, the API may be susceptible to hydrolysis, such
as lofexidine which will be discussed in chapters 4 & 5 of this dissertation. Most
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HP-APIs are likewise poorly water soluble and may require strong organic solvents
to dissolve these compounds which bring concerns with respect to adequate solvent
removal, similar to those addressed previously with respect to secondary drying postspray dry processing. Potency loss may also occur as drug may adsorb to various
process equipment surfaces instead of becoming incorporated within the granulation.
This effect is usually negligible at traditionally higher levels of API content; but for
highly potent compounds, this loss can be substantial relative to the label claim and
may require an overage to account for processing induced losses[90].
Impact of Solvents in Wet Granulated HP-APIs
The solid state phase of the API has long been recognized to influence the stability and performance of a drug product. An API may express a substantial range
of physical phases due to exposure to wet granulation processes including the transformation to various polymorphs[91, 92, 93], solvates/hydrates [94, 95, 96, 97], salt
disproportionation [98, 99], co-crystals, and/or amorphous forms [100, 101] which can
each exhibit substantially different dissolution behaviors and physical and chemical
stability. Interactions between the API, solvent(s) [94, 91, 92], formulation excipients
[95], and process parameters [92, 96] serve to further exacerbate the many possible
outcomes on physical form. Particularly problematic in the case of HP-APIs is that
the low drug concentrations in the formulation severely limit the ability to identify
which physical phase(s) of the API are present, and in what relative amounts. For
example, the most commonly utilized techniques to quantify the solid-state phase
percentage of pharmaceutical materials are powder x-ray diffraction (pXRD), Raman
spectroscopy, and differential scanning calorimetry (DSC), which are recognized to
have detection limits for crystal forms from 0.2-5% [102, 103, 104] and for amorphous
forms from 1-10 % [105, 106, 104] of the total sample weight. With API amounts as
low as 0.01 w/w % in a formulation, it is often unreasonable to accurately quantify
the phase composition of HP-APIs in a given drug product.
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As HP-APIs are frequently dissolved in the liquid binder solution to aid distribution, a range of physical forms can be expected due to preference for varying polymorphic forms when precipitating from different solvents or generation of a glassy state
due to co-dissolution of granule bed excipients (i.e polymers/binder) which stabilize
the amorphous form. If the amorphous phase dominates, then a loss in chemical
stability is expected due to the higher energy state of the glassy form. These effects
can be screened by creating films of the solvent, API, with or without co-dissolved
excipients of interest at high drug-excipient weight ratios to explore the tendency of
the possible physical forms which may precipitate during processing. While this approach can overcome analytical limitations for assessing physical form, it may not be
representative of how the drug will behave at low drug amounts in the true formulation and should be applied with caution. Additionally, the API will be preferentially
distributed on the surface of the granules which will result in greater surface energy
effects as well as increased environmental exposure than if it was sequestered within
the interior of the granules/particles. Hydrolysis/solvolysis during solution preparation and the spraying process are additional risks to product stability due to the
faster degradation occurring in the liquid state relative to solid-state kinetics coupled
with exposure to the solvent(s) and any cosolutes. It is clear that an understanding of
API-solvent interactions from both physical and chemical perspectives are necessary
to facilitate the successful development of a wet granulated HP-API product.
1.6

Objectives

The objective of this dissertation is to provide a general overview and assessment
of the role of solvents in the important methods of spray dried dispersions (SDDs)
and low dosage wet granulations to address concerns related to poorly soluble and/or
highly potent APIs. Light scattering (LS) and dilute solution viscometry (DSV)
techniques have been utilized to assess critical drug-polymer-solvent interactions in
the solution state and explore the mechanisms by which solvent choice may influence
31

SDD physical stability. Next, solid-state characterization techniques were leveraged
to understand how the interplay between a WSG processing parameters, API physical form, and environmental moisture may dictate chemical stability issues. These
learnings then inform the formulation and process statistical design of experiment
(DOE) strategies in the creation of an optimal controlled-release tablet to satisfy the
target dissolution and chemical stability performance requirements. Conclusions and
future work are presented to outline next steps that can be pursued in expanding our
knowledge of complex multi-component solutions which are frequently encountered
in pharmaceutical development.
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CHAPTER 2: APPLICATION OF LIGHT SCATTERING TO ASSESS SOLUTIONSTATE INTERACTIONS IN SDD LIQUID FEEDS

This chapter is a modified reproduction of a portion of the paper by Defrese et
al. (2020), reprinted (adapted) with permission [30]. Copyright (2020) American
Chemical Society.
2.1

Introduction

It is well established that polymers adopt a range of conformations and solution state
organization in response to varying solution environments, though very little work
has been done to understand how these effects might impact the physical stability
and bioavailability of spray dried amorphous dispersions (SDDs). Potentially relevant
solution state polymer-solvent/cosolute interactions include preferential solvation, hydrodynamic size (i.e. polymer swelling or collapse), and solvent quality indicators (i.e.
attractive or repulsive self-interactions). Of particular interest is the investigation of
preferential solvation, defined as the relative attraction or rejection of a cosolvent
and/or cosolute from the local environment of a solvated macromolecule, which often occurs in multi-component macromolecular solutions. As spray drying and other
solvent-based dispersion processing necessitates the use of complex media consisting
of at least three or more components (drug, polymer, solvent(s), and other possible
excipients) - the prevalence of this phenomenon is likely.
This chapter characterizes largely unexplored solution-state properties in model
spray dried dispersion feed solutions using both dynamic and static light scattering
techniques to add greater context and guidance in studying these information rich
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materials. These systems are found to exhibit complex non-intuitive behavior which
serve to highlight the potential utility of preferential solvation in spray dried dispersion processing and stability. It is hypothesized that solution-state organization of
the liquid feed can be engineered and translated to the solid-state for the optimization
of SDD properties.
2.2

Theoretical Background

Dynamic Light Scattering (DLS)
DLS is a powerful technique with broad application in the polymer, nanoparticle,
and biomedical sciences as evidenced by its widespread utilization to provide detailed
sample characterization including particle size [71], shape [107, 108, 109, 110], particleparticle interactions [111, 112, 113], colloidal stability [114, 115, 116], aggregation
[117, 107, 118], phase separation [119, 120, 121], and translational and rotational
diffusion coefficients [122, 123, 124].
Alongside the prevalent use of DLS methods, many researchers have highlighted
the need for careful appreciation of inherent differences in data treatment [71, 125,
73] and experimental sensitivity to seemingly negligible amounts of impurities [70,
72]. For example, Franks et al. determined that the different common algorithms
used for data treatment (cumulants, non-negative least squares (NNLS), constrained
regularization method for inverting data (CONTIN), and frequency) often return
non-equivalent results. It was noted that the cumulants method appeared to provide
a minimal amount of variance for monomodal distributions while the conversion of
intensity distribution data to volume distributions can add significant variation to
DLS results [73]. It was suggested that researchers state the evaluation algorithm used
in any analysis and to be hesitant in determining size based on volume distributions,
and instead should rely on intensity-based size results. However, they also noted that
volume distributions are still useful for assigning approximate mass proportions for
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samples with non-monomodal distributions.
Additional considerations in algorithm selection are the expected properties of the
measured sample, the analyte of interest, and its sensitivity to transient species (i.e.
phase separation, agglomeration) or ‘dust’ impurities (i.e. trace insoluble contaminants arising from sample and/or consumable manufacturing processes or aerosols
introduced from the laboratory environment). For example, the cumulants method
is very sensitive to minor amounts of larger particles which can skew the reported
overall diffusion coefficient [71]. In some cases this can be quite useful, as in the
ability to readily detect changes due to small amounts of aggregated protein; while in
other cases this may be detrimental as for small particle size analytes (≤ 20 nm) that
can be rapidly obscured due to the comparably strong scattering of trace impurities
- especially at lower concentration regimes and smaller scattering angles [70].
For non-Gaussian monomodal distributions, NNLS algorithms are preferred due
to their lack of innate assumptions of sample distributions which makes them better
suited for expected polydisperse materials [71], such as synthetic polymers or complex multi-component systems comprising mixtures of drug, polymer, and multiple
solvents as explored in this study. Furthermore, sensitivity to dust can be minimized
by providing resolution of the analyte peak from apparent contaminants or transient
species that are not of primary interest [126]. For these reasons, and also to allow comparison with prior literature results of interest, we have selected the NNLS
algorithm for analysis in this work. For a more detailed overview of the mathematics governing time auto-correlation functions, DLS intensity data analysis, and light
scattering in general, we refer the interested reader to summaries in the literature
[127, 128, 129, 130, 71].
Critical to the study of hydrodynamic size of dilute macromolecule solutions by
DLS is the apparent diffusion coefficient Dapp as determined from the intensity fluctuation data (with higher order virial expansions truncated) [128]:
Dapp (q, c) = Dz,0 [1 + CRg2 q 2 + ...][1 + kD c + ...]
35

(2.1)

Where Dz,0 is the intensity-weighted translational diffusion coefficient extrapolated
to zero concentration and scattering angle, C a characteristic coefficient of the macromolecule, Rg the radius of gyration, q the wave vector, kD the dynamic interaction
parameter, and c the macromolecule concentration. Notably for isotropic Rayleigh
scatterers (i.e. those particles which are less than ≈ 1/20 the size of the wavelength
(λ0 ) of the incident laser in a vacuum), CRg2 q 2 is << 1 and the effect of angle becomes
negligible on the observed diffusion coefficient:
Dapp (c) = Dz,0 (1 + kD c)

(2.2)

This result demonstrates that the concentration of Rayleigh scatterers can impact
the determination of the apparent diffusion coefficient as measured by DLS when
| kD c | is not sufficiently small. This parameter arises from non-ideal repulsive or
attractive inter-particle interactions and is often utilized as an indicator of protein or
colloidal stability in formulation development [111, 112, 113]. At positive kD , particles
are considered stable as they repel one another and move rapidly apart, increasing
their mobility and the observed diffusion coefficient. When kD is negative, the particles are unstable as they become attracted together, slowing their mobility while
potentially forming complexes or aggregates and demonstrating reduced diffusion coefficients.
This parameter is also related to the osmotic second virial coefficient, B22 , a
characteristic thermodynamic factor which describes the relative particle-particle to
particle-solvent interactions [127]:
kD = 2B22 Mw − ζ1 − 2υ

(2.3)

where Mw is the molecular weight of the macromolecule, ζ1 a frictional factor, and υ
the specific volume of the macromolecule.
Both kD and B22 are solvent quality factors which describe the relative strength
of polymer-polymer interactions compared to polymer-solvent interactions. Solvent
quality is an important concept in polymer science which arose from the derivation of
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the ‘theta’ solvent concept per Flory-Huggins solution theory - i.e. a solvent condition
whereby the net excluded volume and excess chemical potential of mixing of a polymer
in a solvent is equal to zero [75]. In theta solvents (B22 = 0), the steric repulsion of the
monomers in the polymer chain are balanced exactly with solvent-mediated attraction
between the monomers and the polymer adopts ideal chain conformations. Conditions in which the polymer-solvent interactions are stronger than polymer-polymer
interactions are known as ‘good’ solvents (B22 > 0) and causes the polymer conformations to swell and increase in size relative to theta solvents. Conversely, solutions
where polymer-polymer interactions dominate are known as ‘poor’ solvents (B22 <
0), leading to a reduction in size as the polymer contracts due to stronger polymer
self-interactions in comparison to polymer-solvent interactions. The range of these
descriptions from ‘poor’ to ‘theta’ to ‘good’ is known as solvent quality. As solvent
quality increases, more polymer-solvent contacts are made, and the polymer swells whereas decreasing solvent quality implies the opposite.
The Stokes-Einstein equation (2.4) describes the relationship between the Brownian translational diffusion coefficient Dz,0 (i.e. the random translational motion of
particles suspended in a fluid arising from collision theory) and particle size via the
hydrodynamic radius (RH ), modeled as that of an equivalent sphere that diffuses at
the same rate as determined under infinite dilution:
Dz,0 =

kB T
6πηs RH

(2.4)

where kB is the Boltzmann coefficient, T the absolute temperature, and ηs the dispersant or solvent viscosity.
Best practice for determination of an accurate hydrodynamic radius requires measurement of a dilution series that is extrapolated to infinite dilution to satisfy the assumption of random Brownian motion [71]. This assumption is violated when | kD c |
is not << 1, as the repulsive/attractive interactions cause changes in mobility that are
no longer random in nature. Only in those cases where particle-particle interactions
are known to be negligible is it acceptable to determine the hydrodynamic radius
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from a single concentration; though it is still necessary to correct for changes in the
sample viscosity unless likewise sufficiently dilute to have minimal impact to diffusion processes. This chapter will highlight the importance of the dynamic interaction
parameter and its relation to static light scattering measurements in understanding
the solution state properties of relevant spray dried dispersion feed stock solutions.
Static Light Scattering (SLS)
SLS is an experimental method which has long been applied to macromolecular solutions to characterize properties such as the molecular weight (Mw ), size (via the
radius of gyration - Rg ), shape (via the Perrin form factor - P (θ)), and thermodynamic behavior (via the osmotic second virial coefficient B22 ). Radiative scattering
methods, including X-rays, neutrons, and light scattering, all rely on measurements of
the time-averaged excess intensity of the scattering contrast arising from the particles
of interest relative to the background intensity [75]. Determination of these properties are typically conducted through a Zimm plot analysis as constructed from the
averaged intensity data measured at multiple scattering angles and concentrations,
which is then extrapolated to zero angle and concentration (with truncation of the
higher order virial expansion terms as before):
1
Kc
=[
+ 2B22 c + ...][1 + CRg2 q 2 + ...]
R(q, c)
Mw

(2.5)

where R(q, c) is the angle and concentration-dependent Rayleigh ratio, and K the
optical constant:
K=

4π 2 n20 dn 2
(
)
λ40 NA dc2 µi6=2

(2.6)

dn
)µi6=2
where n0 is the refractive index of the solvent, NA Avogadro’s constant, and ( dc
2

the differential refractive increment (DRI) at constant chemical potential for all components except the macromolecule, component 2. Simplifying for application to
Rayleigh scatterers results in the following:
Kc
1
=(
+ 2B22 c)
R(c)
Mw
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(2.7)

Typically, equation 2.7 is truncated to the dilute linear region captured by first
two terms, as the higher order terms are often experimentally inaccessible. It is important to consider a few aspects regarding the DRI parameter with respect to SLS.
As the source of the measured excess scattering intensity arises from the difference
of the analyte refractive index with respect to the reference solution - the greater
the disparity in refractive indices between the macromolecule and the reference solution, the stronger the signal observed and lower the concentrations that can be
accurately analyzed (and vice versa) [130]. As

dn
dc

is squared in the optical constant,

any relative error in its determination will be doubled in the errors of Mw and B22
[127, 130]. To minimize systematic errors, measurements should ideally be conducted
at an equivalent temperature and wavelength as the light scattering conditions.
Preferential Solvation
In multi-component solutions, such as in the case of mixed solvent systems or in the
presence of dissolved cosolutes as is necessary in spray dried dispersion processing,
the DRI parameter can also be affected by preferential solvation of the polymer by
the various species in solution (adapted from [131, 132, 133]):
n

X
dn
dn
dn
)µi6=2 = (
)θi +
λi ( )c2 =0
(
dc2
dc2
dθi
i6=2

(2.8)

dn
where ( dc
)θi is the observed polymer DRI at constant volume composition (θi ), λi the
2
dn
preferential solvation coefficient of the ith component, ( dθ
)c2 =0 the DRI with respect
i

to the ith component, holding all other species constant as the concentration of the
macromolecule approaches infinite dilution.
Preferential solvation is a phenomenon which originates from the relative net favorable or unfavorable cosolute-macromolecule local interactions resulting in either
the excess sorption (favorable) or exclusion (unfavorable) of cosolutes to or from the
pervaded volume of the macromolecule. As this pervaded volume, or the volume of
solution spanned by the macromolecular chain, is orders of magnitude larger than its
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occupied volume, the macromolecule can inhabit a substantial volume fraction of the
solution even at low weight concentrations and can thus readily impact the composition of the bulk solution. When present, this phenomena can affect the refractive
index of the bulk and pervaded volumes due to changing concentrations which shifts
the strength of the signal arising from the refractive index contrast (i.e DRI) during
the static light scattering experiment. λi is defined as the rate of change in the bulk
volume fraction of the ith species with respect to macromolecule concentration and
conceptually may be understood as the excess number of ith molecules (γi ) of partial
molar volume (Vi ) that are preferentially adsorbed within the local environment of
the macromolecular chain:
λi ≡ (

γi Vi
dθi
)µi ,c2 =0 ≡ −
dc2
Mw

(2.9)

By convention, a positive value indicates exclusion from the pervaded volume while
negative values represent preferential adsorption within. Dialysis can correct for these
effects by allowing for the exchange of solutes to re-establish the initial bulk volume
fractions; though this is often tedious and prohibitively expensive for materials such
as therapeutic proteins and/or drug cosolutes. In the absence of dialysis of multi∗
component systems, the observed or apparent Mw∗ and B22
can become distorted due

to the effects of preferential solvation. While an experimental static light scattering
approach for determination of λi is generally not feasible for systems in excess of
three components, Benoit and Strazielle developed an accessible relation for ternary
systems, provided the true molecular weight is known or previously measured from a
single solvent system [134]:
λ3 = [(

(dn/dc2 )θ1,3
Mw∗ 0.5
) − 1]
Mw
(dn/dθ3 )c2 =0

∗
B22 = B22
(Mw∗ /Mw )

(2.10)
(2.11)

where subscript 1 denotes the primary solvent, 2 the macromolecule, and 3 the cosolvent or cosolute.
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For mixed liquid systems, the volume fractions and (dn/dθ3 ) can be either computed or measured directly from solution preparations; while for otherwise solid cosolutes such as drug compounds, which are prepared and measured on a mass concentration basis, the conversion to volume fraction is needed. To address this, the
(dn/dc3 ) in the dilute regime can be measured and the Gladstone-Dale equation [135]
used to find the partial specific volume υ of the dissolved cosolute in the pure solvent
to convert concentrations to volume fractions for determination of (dn/dθ3 ):
υ3 =

(dn/dc3 )
θ3
=
n3 − n1
c3

(2.12)

where n1 and n3 are the refractive indices of the pure solvent and cosolute, respectively.
2.3

Materials and Methods

Polyvinylpyrrolidone K25 (PVP) was gifted from Ashland Global Specialty Chemicals Inc. (Covington, KY). The polymer was held at 40 °C under vacuum for at least
24 hours prior to use for removal of residual water content to ensure accurate polymer mass for solution preparations, as PVP is known to sorb substantial moisture
even at ambient conditions [136]. (S)-(+)-2-(6-Methoxy-2-naphthyl)propionic Acid
(i.e. Naproxen (NAP)), ≥ 99.0% purity was sourced from TCI America (Portland,
OR) and purchased through VWR International (Radnor, PA) and used as received.
HPLC grade Methanol and Acetone with maximum specifications of 0.03% (w/w)
and 0.2 % (w/w) water content were purchased from VWR International and used as
received. 0.02 um Whatman Anotop Syringe Filters were sourced from GE Healthcare (Chicago, IL), purchased though VWR International and used as received. The
chemical structures of PVPK25 and Naproxen are shown in Figure 2.1.
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Figure 2.1: Chemical structures of a) PVP and b) Naproxen

Solution Preparation
All solvent mixtures and solutions were prepared by mass under room temperature
conditions. Concentration series of polymer solutions were prepared independently
in volumetric flasks using a previously prepared reference solvent mixture or drug
solution for each selected cosolute/solvent composition. Each solution was allowed to
equilibrate a minimum of 12 hours and sealed with parafilm to inhibit evaporation.
Solutions were then filtered 3-6 times as necessary to remove impurities prior to
characterization. All samples were visually transparent and uniform. No analyte was
observed to be lost due to the filtration process.
Light Scattering
All light scattering data were collected with a Malvern Zetasizer Nano ZS at 25.0 °C
with 5 minutes equilibration time using a low volume quartz cuvette cell. The cell
was pre-rinsed 2 times with filtered sample before final sample loading and cleaned
with a standard washing protocol between samples. Measurements were conducted
at an angle of 173°and averaged from manual settings of 7 measurements consisting
of 60 runs of 5 second duration each, at a position of 4.2 with automatic attenuator
selection. The refractive index and absorption values used for PVP were 1.525 and
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0.002 [137]. The data was processed using the ‘General Purpose’ NNLS algorithm.
Dispersant (i.e. reference solution) viscosity and refractive index measures needed
in support of light scattering were determined as described below. 20 nm filtered
toluene was used as a reference standard with scattering intensity measured at each
applicable attenuator.
The intensity diffusion coefficient for the primary polymer peak was extracted
for dynamic light scattering analysis (DLS) while the mean intensity count rate
was extracted for static light scattering (SLS) analysis. Intensity peak analysis was
used to minimize noise from errant dust particles and to distinguish between drug
and polymer diffusivity peaks where applicable. No observations of temporal effects
or in-homogeneity, such as increasing phase separation or agglomeration (i.e. no
trending increase of scattering intensity, DLS polydispersity index (PDI), and nonmonomodality or peak size over the time span (≈ 40 min.) of measurements) were
observed during this study.
Viscometry
The viscosity of all solvent mixtures (i.e. without dissolved solutes) were measured
using a Rheosense microVisc Viscometer with A05 chip and temperature controller,
conducted at 25.00 (+/- 0.04) °C with an equilibration time of at least 3 minutes for
each new pipette, with 150 uL prime and 60 uL measurement volumes. Each solvent
mixture viscosity was averaged across at least 6 measurements using 2 disposable
pipettes, with at least 3 measures per pipette. If large differences between averaged
pipette measures were observed (> 0.015 cP), a third pipette with at least 3 additional
measures was conducted and averaged to reduce variance attributable to deviations
in pipette dimensions.
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Refractometry
Refractive index (RI) measurements in support of light scattering studies were conducted using a Carl Zeiss Abbe Refractometer with wavelength of 589 nm at room
temperature conditions. Each sample was measured twice and averaged for use in the
determination of differential refractive increments (DRIs).
Residual Water Assessments
To assess the potential impact of residual water on the static light scattering measurements, 20% (w/v) 3Å activated molecular sieves were added to the as received
HPLC grade acetone and methanol solvents with maximum specifications of 0.2%
(w/w) and 0.03 % (w/w) water content. After both 24 and 48 hours exposure to the
molecular sieves, mixtures were prepared from the solvents at 0-88% (θACE ), consistent with ratios evaluated in the light scattering studies with the polymer, with RI
measurements conducted as previously described.
Data Analysis and Presentation
Statistical analysis and graphs prepared in excel with visualization aided by Daniel’s
XL Toolbox addin for Excel, version 7.3.2 [138]. All error bars represent 95% confidence intervals as determined by regression analysis unless stated otherwise. Data
Thief was used for the extraction of data from graphs in the literature for comparison
and analysis [139].
2.4

Results and Discussion

Dynamic Light Scattering
In order to characterize diffusion interaction parameters and hydrodynamic diameters
for comparison to prior literature results, we evaluated several concentration series
of polymer solutions by DLS ranging from 2-50 mg/mL at dispersant compositions
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of naproxen in methanol at 4.7% θN AP (i.e. 50 mg/mL) and solvent mixtures of
acetone in methanol ranging from 0-88% θACE . For each solvent or reference solution
condition, the peak apparent diffusion coefficient was extracted and plotted against
concentration for determination of the diffusion coefficient at infinite dilution from
the extrapolated intercept and the diffusion interaction parameter from the linear
slope according to equation (2.2) (figure 2.2).

Figure 2.2: Example plot of Dapp vs. C for PVP in methanol with linear regression
fit.
The fitted diffusion coefficients and interaction parameters from the DLS data at
each solvent condition are compiled in figure 2.3 and plotted against the acetone volume fractions in methanol (or the single solution of θN AP in methanol, respectively).
Focusing first on the diffusion coefficients, we can observe that polymer mobility increases substantially with rising acetone content as indicated by a near doubling over
the range of investigated solvent mixtures. In contrast, a somewhat more restricted
movement is observed in the presence of naproxen as indicated by a loss in diffusivity compared to the pure methanol system. These mobility differences are primarily
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attributable to the range of dispersant viscosities explored, despite seemingly small
differences of at most ≈ 0.3 cP between all systems with a span of 0.313-0.630 cP. This
highlights the sensitivity of the diffusion coefficients and thus hydrodynamic diameters to accurate viscosity measurements, which can be experimentally difficult at such
low absolute viscosity values. The implications of errors in viscosity measurements
on DLS data will be addressed in greater detail in following discussions.

Figure 2.3: DLS Summary plot: D0 (◦) and kD (•) vs θACE . Mobility (D0 ) increases
while solvent quality (kD ) is reduced with additional acetone content. Both mobility
and solvent quality are reduced in the presence of naproxen in methanol.  represents
the θACE found to be at or near the solubility limit (S Limit) of PVP, with a kD value
of 0 included to describe continuing loss of solvent quality. M and N are the results
for PVP in the presence of 50 mg/mL NAP in methanol. Trace lines are included as
an aid to the eye. Error bars are 95% confidence intervals.
The larger, positive diffusion interaction parameters that persists until ≈ 30%
θACE demonstrate strongly repulsive polymer-polymer interactions which is indicative
of a ‘good’ quality solvent where polymer-solvent interactions are preferred. This self
repulsive behavior begins to decay with increasing acetone content as the polymer
approaches its solubility limit near ≈ 88% θACE , as deduced by the positive kD value
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approaching 0 with increasing θACE (figure 2.3). The diamond symbol marks the
θACE at which PVP solubility was observed to be insufficient to allow for DLS analysis
(i.e. precipitate formed during sample handling and filtration), from which it can be
inferred that kD must be ≤ 0. The trending loss of solvent quality with increasing
θACE is expected due to the known ‘poor’ solvent character of PVP in acetone rich
solvent conditions [22]. It is possible that critical transition points may exist near
30 and 50% θACE where the trends of D0 and kD appear to change most sharply is
response to changing solvent composition. Notably, there is also a substantial drop
in kD in the presence of naproxen, which indicates that ‘solvent’-polymer contacts
are less favored in comparison to the drugs absence. As naproxen is a carboxylic acid
which is known to adopt stable dimers[140], this change in polymer behavior may be
due to preferential naproxen-naproxen self-interactions or the formation of similarly
strong methanol-naproxen contacts such that the polymer is less able to maintain
stable solvent connections.
After converting the diffusion coefficient to the hydrodynamic radius via equation
(2.4) and plotting vs. θACE alongside prior literature results [15], we see behavior
that is more consistent with the kD results. The polymer size appears to swell up
to ≈ 25% θACE , before contracting at ≈ 30% then staying relatively constant or
possibly trending with a slight rise then decrease as the amount of acetone increases
(figure 2.4). RH was also determined in the presence of 50 mg/mL NAP in methanol,
with no meaningful change in comparison to pure methanol; in contrast to the initial
diffusivity and interaction parameter results. This discrepancy with the diffusion
coefficient can be attributed to the increased dispersant viscosity arising from the
dissolved naproxen rather than any difference in RH , though the change in kD due to
naproxen appears significant and indicates a meaningful loss of solvent quality with
co-dissolved drug in methanol.
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Figure 2.4: RH vs. θACE in the absence (◦) and presence (M) of 50 mg/mL NAP in
methanol from this work. Data extracted from reference [15] measured at conditions
of 35 mg/mL PVP in the presence of 15 mg/mL NAP () and 25 mg/mL PVP in the
presence of 25 mg/mL NAP () respectively. Lines are a trace for this work with 2nd
order polynomial fits for literature data, included as an aid to the eye. The results
from this work differ significantly from reference [15]. Error bars from the literature
data are standard deviations while those from this work are 95% confidence intervals.
When assessing the outcomes between RH and kD , it appears that the diffusion
interaction parameter may be the more sensitive indicator of solvent quality and/or
polymer-cosolute interactions. For example, at higher acetone content and also with
co-dissolved naproxen, it can be seen that the reduction in kD is much more rapid and
apparent in comparison to RH (figures 2.3 and 2.4). Overall, both parameters agree
fairly well with each other, increasing in hydrodynamic size along with increasing
solvent quality behavior with an R2 of 0.755 determined from a linear correlation
plot of RH vs kD (figure 2.5). These results demonstrate the value of additional
context and supporting information that an assessment of a dilution series provides
in comparison to single concentration DLS measurements.
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Figure 2.5: Correlation plot of the Stokes’ RH vs kD , with equation and R2 of the
linear fit. (•) is PVP in the methanol-acetone solvent mixtures and (N) is in the
presence of 50 mg/mL NAP in methanol. The greater change of kD in comparison
to RH highlights the potential of kD as a more sensitive parameter to assess solvent
quality and/or cosolute-polymer interactions. The relatively strong R2 indicates internal consistency between the parameters in describing the behavior of the polymer
in solution. Error bars are 95% confidence intervals.
It is also important to describe how and why our results differ significantly from
prior literature [15], where values of RH were found to range from ≈ 1.8 − 3.2 nm,
in comparison to this work which falls within a range of ≈ 4.9 − 5.9 nm for the same
systems (figure 2.4). The literature values are surprisingly smaller than would be
expected for a polymer of this molecular weight and contain an apparent minimum
occurring between 25-50% θACE before increasing in size at 75% [15], contradicting
the typical expectation of polymer collapse as the solubility limit is approached. It
should be noted that the literature work presented was carried out at either constant
concentrations of 35 mg/mL PVP in the presence of 15 mg/mL NAP or 25 mg/mL
PVP in the presence of 25 mg/mL NAP respectively at varying θACE . In this work, we
have first extrapolated to zero concentration and primarily conducted measurements
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in the absence of naproxen, except for the pure methanol solvent system which was
also evaluated with co-dissolved 50 mg/mL NAP in methanol.
These discrepancies can be explored further in additional related work [16] where
the hydrodynamic size was evaluated at a constant combined 20 w/v% (i.e. 200
mg/mL of total solids) of NAP and PVP at varying drug and polymer fractions. If
the presence of naproxen has a minor or negligible effect on hydrodynamic size of
PVP in methanol as found in this work, then these data may be treated as a pseudodilution series for extrapolation to the Stokes’ radii (figure 2.6). From this treatment
of the data, we demonstrate a Stokes’ radii of ≈ 5.5 − 6 nm, similar to our findings
of ≈ 5.25 nm when in the presence of 50 mg/mL naproxen and much greater than
the results published in the initial reference[15]. We should note that this is only
an approximation as a proper dilution series for extrapolation should be conducted
in a specific reference solution, i.e. at a constant naproxen concentration, where in
the reference source the drug amount is varied due to holding % solids in solution
constant.
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Figure 2.6: Hydrodynamic radii (RH ) vs. PVP concentration with varying NAP
amounts as extracted from the bimodal (◦) and unimodal (•) distributions respectively, per reference [16]. When a dilution series and extrapolation is applied to the
literature data, similar RH of ≈ 5.5 and 5.9 nm are found which are comparable to
results from this work (5.3 nm with 50 mg/mL NAP in methanol). Linear regression
fits and trend lines included to demonstrate extrapolated size from the intercepts.
Error bars are standard deviations.
Per this study [16], development of a bimodal distribution was observed at lower
polymer/higher drug content where the larger population grows in size as naproxen
concentration increases - this was considered a ‘remarkable’ observation, yet we believe
the explanation is straightforward. We suggest that the generation of the bimodal
distribution with increasing naproxen content is likely due to phase separation and/or
crystallization of the drug as the solubility limit of naproxen in methanol has been
previously determined to range between ≈ 50 and 85 mg/mL [141, 142, 143], while
the reference data assessed concentrations of NAP up to 110 mg/mL.
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Table 2.1: Literature viscometry data per reference [15]
S0

S1

S2

S3

PVP (mg/mL)
NAP (mg/mL)

0
0

22.5
27.5

35
15

50
0

θACE

η0

η1

η2

η3

0.56a
0.48a
0.39a
0.30a

0.63
0.49a
0.44a
0.34a

1.09
0.76
0.65
0.61

0
0.25
0.50
0.75

0.58
0.69
0.58
0.46

±0.002
±0.002
±0.005
±0.005

Unexpectedly low viscosity with added solutes in comparison
to the pure solvent mixtures, all table values in centipoise (cP )
S0 : pure solvent mixture viscosities with standard deviations
from n=3 measures
S1 : solutions of 50 mg/mL PVP & 0 mg/mL NAP
S2 : solutions of 35 mg/mL PVP & 15 mg/mL NAP
S3 : solutions of 22.5 mg/mL PVP & 27.5 mg/mL NAP

Additionally, the viscometry data sourced from reference [15] used to calculate
RH appears to be inaccurate, as captured in Table 2.1. In some cases, the measured
viscosity of the solutions containing dissolved PVP and NAP are less than that of
the pure solvents, which should not occur. Furthermore, the viscosities of the pure
methanol-acetone solvent mixtures are neither consistent with our results nor prior
work in the literature [144], which agree well with each other (figure 2.7). It is clear
that per equation (2.4), any error in the measured viscosity will likewise translate to
a similar error in the reported RH . From this, it is clearly demonstrated that the
discrepancy between our hydrodynamic sizes and those in reference [15] (and even
the differences in size due to naproxen content within that same work) are likely due
to both polymer concentration effects attributable to the kD interaction parameter
as well as inaccurate viscometry measurements. Overall, these outcomes illustrate
the importance of conducting a dilution series alongside accurate viscosity measurements for the correct interpretation of DLS data while also highlighting the value in
determination of the diffusion interaction parameter in understanding solution state
behavior of polymer-drug interactions.
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Figure 2.7: Comparison of solvent mixture viscosities vs θACE from reference [15] (),
this work (◦), and reference [144] (M). Viscometry results of pure solvent mixtures
from this work are well behaved and align well with reference [144] in comparison to
reference [15]. Dashed line is 2nd order polynomial fit from this work; dotted line is
3rd order polynomial fit of reference [15], solid line represents predictions from ideal
viscosity of mixing. Error bars represent standard deviations for all data sets.

Static Light Scattering and Refractometry
In order to characterize the true molecular weight, osmotic second virial coefficients,
and preferential solvation parameters of naproxen in methanol and acetone in methanol
at varying θACE , the same solutions were also evaluated by SLS and refractometry
techniques. For each solvent or reference solution condition, the time-averaged scattering intensity was extracted from the light scattering data for determination of the
true (and apparent) molecular weight Mw (Mw∗ ) and osmotic second virial coefficient
∗
B22 (B22
) from the extrapolated intercept and slope of the linear dilute region of

KC/Rθ vs. concentration according to equation (2.7).
However, before moving forward with SLS and related RI measures, the potential
effects of trace residual moisture on the refractive index measurements in the HPLC
grade solvents need to be considered. It is expected that the measurements expected
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to be most affected due to trace water are the preferential solvation parameters. These
are the most susceptible to misinterpretation due to limitations of SLS analysis for
multi-component systems in excess of 3 components. The presence of 4 or more
components makes it difficult to discern which component is causing the distortion of
the molecular weight in mixed solvent conditions arising from the changes in refractive
indices per equation 2.8.
To address this concern, we have conducted both a theoretical and empirical
assessment to explore the maximum potential impact of residual water content on the
refractive index of the solvent mixtures at the maximum specification of the HPLC
grade solvents. We searched the literature for experimental data[145] of the refractive
indices of acetone, methanol, and water mixtures to calculate the expected change in
refractive index due to the presence of residual water, with model parameters from
[145] in terms of mole fractions of the solvent mixtures explored in this work, as
contained in table 2.2 below:
Table 2.2: Ternary RI Model Coefficients for Acetone, Methanol, & Water mixtures
[145]
Coefficients by Polynomial Order
Solvent

1

ACE
MeOH
H2O

1.4306
1.3503
1.3573

2

3

-0.2059 0.2263
0.0757 -0.1094
-0.0093 0.0393

4
-0.0963
0.0554
-0.0542

We calculated the refractive indices of the mixtures both with (column 6, assume
xH2 O at max spec limits) and without (column 7, assume xH2 O ≈ 0) the presence of
water in the solvents and took the difference between these results (column 8) per
table 2.3. In all cases, the presence of water would be expected to reduce the observed
refractive index in the range of 3.86E-06 to 8.32E-05 RI units, with a trend of greater
reductions with increasing acetone content. These effects would be expected due to
the maximum of 0.2 % residual water in acetone vs 0.03 % in the case of methanol,
as well as the larger relative difference in the refractive indices between acetone and
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water, in comparison to those differences between methanol and water, which are
much closer in value.
However, there are several key points to recognize why this would not be expected
to affect our results. The maximum expected change in refractive index is very
minor and is almost an order of magnitude below the rated sensitivity limits of our
refractometer (2E-04), which is thus expected to be below the limits of detection
in our experiment. Additionally, this example assumes the worst case conditions –
specifically, that the water content was at or near the specified maximum within the
solvents, and that the water must be partitioned fully in one phase or the other to
maximize the change in refractive index on the impact to the preferential solvation
parameter. This is highly unlikely as water interacts favorably with all components in
solution (acetone, methanol, PVP), with the exception of naproxen – though naproxen
is present in limited amounts and only present as a cosolute in methanol, which had
the least expected water content. This analysis indicates that we should not expect
any meaningful impact on this study due to residual moisture.
Table 2.3: Comparison of theoretical RI differences with and without the presence of
residual water for the studied solvent mixtures
Assume XH2 O = 0

Assume XH2 O at max

Refractive Index Results

XM eOH

XACE

XM eOH

XACE

XH 2 O

w/ H2 O

w/o H2 O

∆nD

1.000
0.900
0.845
0.800
0.700
0.645
0.600
0.500
0.400
0.300

0.000
0.100
0.155
0.200
0.300
0.355
0.400
0.500
0.600
0.700

0.99947
0.89914
0.84404
0.79890
0.69874
0.64381
0.59867
0.49868
0.39878
0.29896

0.00000
0.09973
0.15451
0.19939
0.29895
0.35356
0.39844
0.49783
0.59715
0.69638

0.00053
0.00112
0.00145
0.00171
0.00230
0.00263
0.00289
0.00348
0.00407
0.00466

1.32700
1.33391
1.33686
1.33893
1.34260
1.34420
1.34535
1.34752
1.34936
1.35101

1.32700
1.33390
1.33685
1.33891
1.34256
1.34415
1.34530
1.34746
1.34928
1.35093

-3.86E-06
-7.00E-06
-1.39E-05
-2.10E-05
-3.82E-05
-4.70E-05
-5.33E-05
-6.41E-05
-7.20E-05
-8.32E-05

To support these theoretical outcomes with experimental confirmation, we next
dried the methanol and acetone solvents using freshly activated 3Å molecular sieves
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added at 20% m/v ratios and measured the refractive indices of the solvent mixtures
after 24 and 48 hours exposure for comparison to the as received solvents (i.e. ‘wet’),
with results below:

(a)

(b)

Figure 2.8: Refractive index results from a) the as-received solvents, and after 24
and 48 hours exposure to 20 % w/v 3Å molecular sieves and b) changes in refractive
index in comparison to the as-received solvents
Per a) in figure 2.8, we can observe no obvious change in the refractive indices
after exposure to molecular sieves for 24 and 48 hours. To explore any potential
differences more closely, the observed changes in refractive indices after 24 and 48
with respect to the as received solvents were plotted in panel b). There is no negative
trend with acetone content as would be expected from the theoretical analysis ; nor is
there otherwise any meaningful differences in general with respect to exposure time
to the molecular sieves. Taken together, we believe these data demonstrate that any
potential effects of residual moisture are negligible and below the limits of detection
in this study. As such, evaluation of these systems by SLS and related refractometry
results follow in figures 2.9, 2.10, 2.11, and 2.12.
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Figure 2.9: RI results of NAP in methanol without PVP (N), and acetone-methanol
solvent mixtures from this work (•), in which the trends agree well, though elevated
in comparison to reference [146] (). The RI differences observed are attributable
to conducting measurements at room temperature rather than 25 °C, due to lack of
temperature controls on the RI instrument. DRI results of NAP in methanol without
PVP (), PVP solutions at varying θACE content (◦), and PVP in the presence of
NAP in methanol (M). Error bars are standard deviations for RI measurements and
95% confidence intervals for DRI results.
The DRI of PVP in the reference solution and of NAP in methanol were determined from the slopes of the refractive index (RI) vs. concentration plots. The DRI
of acetone in methanol as a function of θACE was extracted from data in reference
[146] due to the greater precision of their measurements. Per figure 2.9, the refractive
index trends of acetone-solvent mixtures aligns well with prior literature results from
reference [146], though our absolute values are somewhat elevated. This is most likely
from conducting measures at room temperature conditions of ≈ 21°C instead of 25°C
due to lack of available temperature control instrumentation. This is not expected to
have a substantial impact on the DRI measures (i.e. slopes) required for determination of preferential solvation effects and the relative % errors achieved ranged within
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an acceptable 0.97-5.27 %. The DRI of PVP decreases with increasing acetone and
naproxen content which is expected as both have refractive indices closer to PVP
than that of methanol such that the addition of polymer has less of an impact on the
overall solution refractive index. Despite this loss in scattering contrast, the polymer
DRIs are all well above the minimum recommendation of 0.100 ml/g required for
good signal to noise in support of SLS studies. [130].
An example SLS plot of PVP in methanol is shown in figure 2.10. Notably, the
Mw and B22 parameters must be derived from only the dilute linear portion of the
SLS plot per the truncated form of equation 2.7:

Figure 2.10: Example SLS and DRI () plots vs PVP concentration in methanol. SLS
parameters are extracted from the dilute linear region (•) prior to onset of nonlinear
behavior (◦) attributable to higher order virial terms.
These results are extended to all solvent mixtures explored and captured in 2.11.
∗
Per figure 2.11, the apparent Mw∗ and B22
behavior as a function of θACE does not

follow an obvious trend, similarly rising and falling at various acetone amounts with a
surprisingly greater Mw∗ when in the presence of naproxen. These deviations from the
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true Mw are related to the extent of preferential solvation and the DRI for acetone
(≈ 0.02 − 0.04 ± 0.00068) and naproxen (0.286 ± 0.0038) in methanol respectively,
per equation (2.10). As the DRI of naproxen is much greater compared to acetone,
this can result in a substantial shift of Mw∗ even for comparatively smaller preferential
solvation effects. This impact of a large cosolute DRI on the observed Mw gives rise
to questions about the validity of equation (2.11) in the determination of the true
B22 . This relation implies that even in conditions of minor preferential solvation, a
substantial change in solvent quality would result, which does not seem an appropriate
conclusion.

∗
Figure 2.11: Summary B22
(◦ w/o, M w/ NAP) and Mw∗ (• w/o, N w/ NAP) results vs
θACE . The horizontal dashed line represents true Mw determined from pure methanol
solvent that serves as a reference of the extent of preferential solvation. Remaining
dashed lines are a trace included as an aid to the eye. Solvent quality trends lower
with increasing acetone except for maxima located at 17 and 44% θACE . It also
rises substantially in the presence of NAP, in contrast to DLS and DSV observations.
Strong preferential solvation effects are indicated at 17, 25, 44, and 50% θACE as well
as in the presence of NAP as evidenced by Mw∗ observations that differ significantly
from the true Mw .

Furthermore, if the addition of a cosolute to a binary polymer-solvent system
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results in the preferential exclusion of the solute, as demonstrated here by the positive
λ for NAP when added to PVP in methanol, one would expect that the addition of
such a cosolute would reduce the solvent quality - otherwise, it would not be excluded.
It is clear that in cases where the DRI of the cosolute of interest is very large, the
shift in Mw∗ (per 2.10) may be more attributable to the rate of the refractive index
changes of the bulk composition rather than to the magnitude of change in solvent
quality arising from preferential solvation. This implies that for large DRI of cosolute
in the absence of the macromolecule, this relationship may no longer be appropriate
and may be worth further investigation to resolve, which is beyond the scope of this
work.

Figure 2.12: Summary B22 (• w/o, N w/ NAP) and λ (◦ w/o, M w/ NAP) results vs
θACE . The general trend of loss in solvent quality with increasing acetone is observed,
except for those conditions which exhibit strong preferential solvation. Naproxen is
excluded from the local polymer environment when co-dissolved in methanol. Horizontal dashed line is the condition λ = 0, from which deviation demonstrates the
extent of preferential solvation effects. λ ≥ 0 indicates exclusion, ≤ 0 indicates solvation. Other dashed lines are a trace included as an aid to the eye.
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From the measured DRI and Mw , λ and true B22 values were calculated per
equations (2.11) and (2.10) and plotted in figure 2.12, where the two parameters track
the behavior of the apparent results closely. Acetone is either excluded from the local
polymer environment, as indicated by positive preferential solvation coefficients at
varying θACE , or the compositions of the bulk solution and pervaded volumes are near
equivalent for conditions where λ is not significantly different from zero. Interestingly,
both λ and B22 were found to have local minima at ≈ 30% and 55 % volume fractions
(or ≈ 4:1 and 3:2 moles of methanol to acetone respectively) which corresponds with
the prior conditions of sharp changes with collapsing polymer conformation and/or
reduction in solvent quality per the DLS results. Similarly those conditions with
positive λ at 17, 25, 44 and 50% volume fractions are generally consistent with greater
or increasing size and solvent quality observed by DLS. As PVP and acetone are well
known to have unfavorable interactions, the exclusion of acetone in favor of excess
methanol improves the relative solvation of the polymer. These results demonstrate
the explanatory power of preferential exclusion in understanding the non-intuitive
changes of polymer-solution interactions identified initially by DLS.
Naproxen is likewise excluded in the presence of methanol, though not as strongly
as acetone at some conditions, despite the large Mw shift previously described. This is
an important finding as it provides an additional mechanistic reasoning for the reduced
stability of spray dried naproxen-PVP dispersions arising from solutions containing
methanol as demonstrated previously in the literature [15]. Ideally, knowledge of
naproxen preferential solvation/exclusion would be known as a function of θACE in
quaternary solutions as well. Unfortunately this SLS technique is not suitable for
the discernment of preferential solvation for solutions containing more than three
components due to the inability to determine which components, either in whole or
in part, are responsible for the shift on molecular weight arising from changes in
polymer solution DRIs, per equation (2.8).
However, as the literature [15] observed improved physical stability of those dis-
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persions prepared with increasing acetone content, this may imply that the drug becomes less excluded or even preferentially solvated as the volume fraction of acetone
increases. The role of solvent interactions in driving such behavior may be understood due to the ability of the solvent systems to either maintain or disrupt strong
self-associations of naproxen. Naproxen has been found to preferentially form dimers
in proton donating solvents (i.e. methanol), while proton accepting solvents (i.e. acetone) substantially reduces the prevalence of these dimers in solution [147] - these
observations may also help explain why naproxen exhibits a 2-3x greater solubility
in acetone than methanol [142]. Naproxen dimer formation in the presence of high
methanol content may likely prevent the ability to develop strong interactions with
the hydrogen-bond accepting groups of the polymer. If such self-association behavior
is the source of naproxen preferential exclusion, it may be likewise appropriate to
frame this interaction instead as the exclusion of the polymer from the local environment of the API in favor of naproxen-naproxen contacts. As the solvent system
is modified with increasing acetone to disrupt this behavior, then naproxen may be
more readily available to maximize drug-polymer contacts within the pervaded volume, which can then aid in the development of a more homogeneous and stable spray
dried dispersion.
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Figure 2.13: Illustration of potential effects of RH and λ on post-processing SDD
solid-state homogeneity. Polymer swelling and preferential inclusion of drug in the
local polymer environment may lead to improved product uniformity and stability.
Per figure 2.13, a qualitative illustration has been constructed to describe the
potential combined roles that both polymer conformation (i.e. hydrodynamic size)
and drug preferential solvation may play in controlling the homogeneity and physical
stability of spray dried dispersions. This image shows that polymer conformation
alone may not tell a sufficiently detailed story of solution state behavior, while the
consideration of preferential solvation can help add rich context in understanding the
prevalence and strength of drug-polymer interactions in solution. One can imagine
solvent conditions where even though solubility of drug and polymer might be maximized in support of processing needs, poor dispersion stability may result - either by
drug-solvent interactions dominating drug-polymer interactions such that the polymer may be excluded and therefore collapse, or by polymer-solvent interactions which
dominate drug-polymer interactions such that the drug is instead excluded from the
local polymer environment; or from some combination of these effects that either way
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reduces the strength of net drug-polymer interactions and places a risk on the critical
quality and performance attributes of the drug product.
2.5

Conclusions

In this work we have demonstrated that the evaluation of dilution series and conducting accurate viscometry measurements are important to ensuring the appropriate interpretation of DLS studies. The diffusion interaction parameter, kD , has been
highlighted as a readily accessible and potentially sensitive solvent quality indicator
useful for understanding drug-polymer-solvent interactions in spray dried dispersion
solutions.
Strong preferential solvation was found to correlate with conditions of unexpected
and out-of-trend behavior that were observed in the DLS studies. The solvent ratios
where acetone was found to be preferentially excluded were consistent with outcomes
indicating improved solvent quality and polymer size, revealing its potential utility
as a mechanistic explanation for understanding solution-state properties in complex
media. Importantly, naproxen was likewise found to be preferentially excluded in
pvp-methanol solutions, in agreement with DLS outcomes and aligning with a prior
report in the literature [15] of poor naproxen-PVP dispersion stability when sprayed
out of methanol.
Overall, PVP is found to consistently exhibit complex non-intuitive behavior in
mixed solvent and solvent-solute systems across a variety of light scattering techniques. These findings underscore the need for a greater understanding of the implications of preferential solvation and related solution-state parameters in the design
of multi-component systems that are inherent to spray-dried and solvent-based dispersion processing.
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2.6

Future Work

Extension to systems of four or more components
Notably, recent work by Calero-Rubio et al. [148] provides an experimental technique capable of overcoming the short comings of light scattering with respect to
preferential solvation, which is limited in the characterization of systems of no more
than three components. Their method leverages the application of inverse KirkwoodBuff solution theory combined with highly precise density measurements in order to
describe the preferential interactions of specific cosolutes with macromolecules in solutions containing any arbitrary number of constituents. This approach should be
similarly applicable to spray drying feed solutions and other solvent based processing
methods, offering a promising future for the exploration of solution state properties
in amorphous dispersions.
Assessing the translation to the solid-state
Once drug-polymer interactions in the solution state are well understood, preparation
of the solid state dispersion can be conducted via the spray drying process. By varying
the solvents used, droplet size distributions, evaporation rates, and phase behavior
will be impacted during the drying process as previously described in chapter 1. As
such, each solvent system should be well understood and characterized to allow for
standardization of these effects as best as possible, to support the meaningful comparison when spraying out of different solvent conditions. Droplet size distributions
can be measured by laser diffraction and atomization parameters tuned until systems
produce equivalent distributions. Evaporation rates can be controlled by varying
process gas temperature and flow rates. Phase behavior can not be well controlled
due to the material and composition dependence nature of these effects. However,
the effects of varying phase behavior can either be quantified by the development of
multi-component phase diagrams and/or operating at very rapid evaporation rates to
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minimize the extent of phase effects during the drying process. It is likely useful to
explore a range of evaporation rates for each solvent system to better understand interactions between evaporation and homogeneity of resulting dispersions as a function
of solvent composition.
Characterization of the nano-scale miscibility of solid state dispersions is no simple
task. However recent progress in the fields of solid-state NMR techniques offer promise
in better understanding miscibility limits of solid dispersions [149, 150]. Furthermore,
the use of solution calorimetry in solid dispersions pioneered by the Marsac lab, has
been utilized to directly measure the strength of drug-polymer enthalpic interactions
in the solid state which can be used to assess relative interactions between dispersions prepared out of different solvents or process conditions [151]. Lastly, additional
techniques holding great promise for the detailed characterization includes scattering technologies such as small angle neutron and x-ray scattering (SANS, SAXS).
Both techniques offer sub nanometer resolution of material properties including polymer conformation and drug preferential solvation in the solid-state by SANS through
analogous measures as to those conducted by light scattering or density (i.e. compositional) uniformity by SAXS [152, 153]. SANS is a niche technique that requires
a synchrotron radiation source for operation which limits its broader utility as well
as required deuteration and/or carbon-13 labeling of system components to provide
scattering contrast for analysis [153].
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CHAPTER 3: APPLICATION OF VISCOMETRY TO ASSESS DRUG-POLYMERSOLVENT INTERACTIONS IN SDDS LIQUID FEEDS

This chapter is a modified reproduction of a portion of the paper by Defrese et
al. (2020), reprinted (adapted) with permission [30]. Copyright (2020) American
Chemical Society.
3.1

Introduction

Analysis of polymer solutions by dilute solute viscometry (DSV) is a classical technique originating from the early days of macromolecular science. Viscometry produces
data that is both complimentary and orthogonal to light scattering measurements,
and is commonly utilized in tandem for the comprehensive characterization of polymer solutions. In conjunction with a concentration detector (UV or RI detector) and
size exclusion chromatography (known as triple detection SEC), the combination of
these techniques are still among the state of the art for the characterization of industrial polymers. DSV allows for the determination of parameters such as the intrinsic
viscosity ([η]) and Huggins’ coefficient (kH ), which are analogous to the hydrodynamic
radius (RH ) and solvent quality parameters (kD , B22 ) identified by light scattering.
Relative to light scattering, viscometry approaches offer some practical upsides.
Notably, light scattering equipment can be cost prohibitive for many labs (typically
ranging from $30-100k) and sample preparation is often very tedious due to the need
for stringent removal of particulate impurities and thorough cleaning protocols. Light
scattering samples are ideally prepared in a clean room environment to minimize risk
for additional contamination of particles introduced from the laboratory environment.
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In comparison, viscometry samples are much more forgiving, and quality instrumentation for the purpose of intrinsic viscosity measurements ranges from the low hundreds
to low tens of thousands of dollars. While the highest quality rheometers can easily
approach or exceed light scattering costs, there are not necessary for most applications. A major drawback for rheometry is that molecular weights of samples are
determined on a relative basis rather than on an absolute basis as is the case with
light scattering [75]; which can limit the value of some measurements and/or require
additional measurements for the development of robust calibration curves.
This purpose of this chapter is to establish the preferred methods for the viscometric analysis of spray dried dispersion solutions and compare these outcomes to
those found by light scattering. As such, we have evaluated the systems previously
explored in chapter 2 by DSV to validate the findings from light scattering as well
as explored additional systems of PVP in dichloromethane-acetone solvent mixtures
which have been of interest in the literature [15].
3.2

Theoretical Background

Intrinsic viscosity is classically determined from viscosity measurements conducted on
a dilution series that are treated according to the truncated empirical Huggins and/or
Kraemer functions with extrapolation to zero concentration and shear rates[75]:
η − ηs
= [η] + kH [η]2 c + ...
ηs c

(3.1)

ln(η/ηs )
= [η] + kK [η]2 c + ...
c

(3.2)

[η]red =
[η]inh =

kK = kH −

1
2

(3.3)

where [η]red is the reduced viscosity, η is the viscosity of the solution, ηs is the
viscosity of the pure solvent or reference solution without dissolved macromolecule
viscosity, [η]inh is the inherent viscosity and kK is the Kraemer’s coefficient.
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Physically, the intrinsic viscosity captures the contribution of a solute to the viscosity of a solution and is related to the shape and size of the solute in solution
[75, 130]; while the Huggins’ coefficient is the second virial coefficient arising from the
virial expansion of the solution viscosity under low concentrations, just as was done
with respect to the DLS and SLS analysis for kD and B22 , respectively. The Kraemer
function is derived from the Huggins’ equation, through the rearrangement of viscosity terms, then taking the natural logarithm of the entire function and substituting
an expansion of the logarithm on the right side of the equation, which produces an
analogous structure to the Huggins’ treatment [75]. Traditionally, [η] and kH are
determined using both equations as a form of quality control, such that if they agree
- then the results are valid; otherwise lower polymer concentrations should be used
and the analysis repeated until the results are consistent across both approaches [75].
An additional concern with DSV measurements is understanding and mitigating the effects of shear experienced by the particles during the course of the measurement. Polymer solutions are well known to exhibit a range of possible nonNewtonian behaviors (i.e. non-linear change in viscosity with variable shear rates),
including most prominently shear-thinning (negative deviation with increasing shear)
and shear-thickening (positive deviation with increasing shear) phenomena. Ideally,
determination of [η] and kH should be conducted at multiple shear rates to rule out
non-Newtonian behavior and/or extrapolated to the zero shear rate to prevent these
affects on the DSV analysis.
With [η] reliably known, we can then calculate a viscometric analog of the hydrodynamic radius, Rη for direct comparison to the DLS results [130]:
Rη = (

3[η]Mw (1/3)
)
10πNA

(3.4)

Where Mw is the polymer molecular weight and NA is Avogadro’s constant. It should
be noted that Rη is not derived from an absolute measure of polymer size, but is
relative to the thermodynamic quality of the solvent in which it is measured. This
results in the expectation of the viscometric radius to be less than or equal to the
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hydrodynamic radius RH determined by light scattering, i.e. Rη ≤ RH . Rη will
increase in similarity to RH as the Mark-Houwink-Sakurada (MHS) solvent factor
approaches unity, which is generally a rare occurrence [130, 154].
Wolf ’s Intrinsic Viscosity
A limitation of the Huggins and Kraemer approaches for measuring intrinsic viscosities
is that for strongly electrostatic self-interactions, these traditional treatments are not
appropriate. To address this limitation, B.A. Wolf derived a relationship for the
intrinsic viscosity starting from the condition that the solution viscosity is a function
of state and incorporating additional parameters to describe the behavior of charged
macromolecules in solution [155]:
ln(η/ηs ) =
B=

c[η] + Bc2 [η][η]•
1 + Bc[η]

0.5 − kH
1 − ([η]• /[η])

(3.5)
(3.6)

where B is a system specific constant and [η]• a parameter which accounts for electrostatic effects on hydrodynamic parameters with varying ionic strength, which is further assumed to be zero for uncharged solutes. This equation is a generalized solution
that has been shown to correctly determine the intrinsic viscosity for both uncharged
and charged polymers under a variety of ionic strength conditions [155, 156, 157, 74].
Xiong et al. then demonstrated that the Wolf plot produces reduced error in
comparison to the traditional Huggins approach and is also more suitable for a wider
range of polymer types including uncharged polymers, polyelectrolytes with and without salt cosolutes, copolymer blends, and star-branched polymers. In order to probe
whether the Wolf plot maintains improved precision of parameter estimates under
mixed solvent conditions, we have likewise analyzed our viscometry data with both
the Huggins and Wolf techniques for comparison. The linearized Wolf plot as simplified for uncharged polymers (adapted from [155]) follows:
1
1
=
+B
ln(η/ηs )
c[η]
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(3.7)

B = 0.5 − kH

(3.8)

Lastly, just as preferential solvation of the cosolvent/solute (λi ) impacts static
light scattering results as discussed in chapter 2, so also are the apparent intrinsic
∗
viscosities [n]∗ and Huggins coefficients kH
likewise affected. Caparros and Bohda-

necky derived corrections for preferential solvation of ternary systems as revealed
through the changing viscosity of the bulk reference solution with varying macromolecule concentration (adapted from [132]):
[η] = [η]∗ −
∗
kH = kH

λi (dηs /dθi )0
ηs

([η]ηs + λi )2 − λi ηs [(d[η]/dθi ) + [η](dηs /dθi )0 ]
[η]2 ηs

(3.9)
(3.10)

where (dηs /dθi )0 and (d[η]/dθi )0 are the differentials of the reference solvent mixture
or solution viscosity in the absence of the macromolecule and the intrinsic viscosity with respect to the ith (i.e. cosolvent/solute) volume fraction respectively. It
should be noted that to determine the true Huggins coefficient in multi-component
solutions within any reasonable confidence requires highly precise measures of preferential solvation as well as the (dηs /dθi )0 and (d[η]/dθi )0 terms, which may often be
experimentally challenging.
3.3

Materials and Methods

Polyvinylpyrrolidone K25 (PVP) was gifted from Ashland Global Specialty Chemicals
Inc. (Covington, KY). The polymer was held at 40 °C under vacuum for at least 24
hours prior to use for removal of residual water content. (S)-(+)-2-(6-Methoxy-2naphthyl)propionic Acid (i.e. Naproxen (NAP)), ≥ 99.0% purity was sourced from
TCI America (Portland, OR) and purchased through VWR International (Radnor,
PA) and used as received. HPLC grade Dichloromethane (DCM), Methanol (MeOH),
and Acetone (ACE) with maximum specifications of 0.05, 0.03, and 0.2 % (w/w)
water content were purchased from VWR International and used as received. 0.02
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um Whatman Anotop Syringe Filters were sourced from GE Healthcare (Chicago, IL),
purchased though VWR International and used as received. The chemical structures
of PVPK25 and Naproxen are shown in Figure 2.1.
Solution Preparation
All solvent mixtures and solutions were prepared by mass under room temperature
conditions. Concentration series of polymer solutions were prepared independently
in volumetric flasks using a previously prepared reference solvent mixture or drug
solution for each selected cosolute/solvent composition. Each solution was allowed to
equilibrate a minimum of 12 hours and sealed with parafilm to minimize evaporation.
Solutions were then filtered 3-6 times as necessary to remove impurities prior to
characterization. All samples were visually transparent and uniform, and no analyte
was observed to be lost due to the filtration process.
Viscometry
The viscosity of all solvent mixtures and solutions were measured using a Rheosense
microVisc Viscometer with A05 chip and temperature controller, conducted at 25.00
(+/- 0.04) °C with an equilibration time of at least 3 minutes for each new pipette,
with 150 uL prime and 60 uL measurement volumes. Each solvent mixture and
solution viscosity was averaged across at least 6 measurements using 2 disposable
pipettes, with at least 3 measures per pipette. If large differences between averaged
pipette measures were observed (> 0.015 cP), a third pipette with at least 3 additional
measures was conducted and averaged to reduce variance attributable to deviations
in pipette dimensions.
Non-Newtonian behavior was investigated at variable shear rates of 2500, 5000,
and 7500 reciprocal seconds (1/s) for the methanol solvent system. As only shear
insensitive typical Newtonian behavior was observed, extrapolation to zero shear for
all solutions was considered unnecessary. Regardless, for each solution shear rates
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were adjusted to the minimum suitable shear rate necessary to keep the pressures
generated during measurements within the rated performance limits of the instrument
to minimize any potential for shear thinning effects as possible.
Data Analysis and Presentation
Statistical analysis and graphs prepared in excel with visualization aided by Daniel’s
XL Toolbox addin for Excel, version 7.3.2 [138]. All error bars represent 95% confidence intervals as determined by regression analysis unless stated otherwise. Data
Thief was used for the extraction of data from graphs in the literature for comparison
and analysis [139].
3.4

Results and Discussion

Figure 3.1: Example DSV plot of PVP in 31% θACE solvent mixture, including the
nonlinear (◦) and linear regions (•) utilized for extrapolation with the Huggins treatment.
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In order to characterize intrinsic viscosity and Huggins coefficients for comparison to
prior DLS and SLS results, we evaluated the same concentration series of polymer
solutions by DSV ranging from 2-50 mg/mL at dispersant compositions of naproxen in
methanol at 4.7% θN AP (i.e. 50 mg/mL) and solvent mixtures of acetone in methanol
ranging from 0-88% θACE . Additional systems of DCM-ACE solvent mixtures were
also evaluated by DSV at polymer concentrations of 2-50 mg/mL with acetone volume
fractions up to 73%, as the precipitation point was found to occur at 82% acetone
content in DCM (compared with 88% for the MeOH system as previously noted
in chapter 2). The DCM-ACE systems were found to be unsuitable for the light
scattering measurements and as such, only the DSV data for the DCM-ACE systems
are presented in this dissertation.
Notably, at lowest polymer concentrations, typically occurring from 2-10 mg/mL,
non-linear behavior was observed when using equation (3.1) (figure 3.1). This is attributed to the inability of the rheometer to detect meaningful viscosity differences at
low absolute viscosities relative to the rate of reduction in polymer concentration when
calculating the reduced viscosity (i.e. the denominator gets smaller as the numerator
does not change due to lack of sensitivity). This effect results in the observation of
rapidly rising [η]red values, though this is only an artifact of insufficient experimental
sensitivity for these conditions. As such, those low concentrations exhibiting nonlinear behavior were excluded from further analysis. Example DSV results can be
seen in figure 3.2.
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Figure 3.2: Example of viscometry functions vs concentration (or C −1 ) for PVP in
methanol with linear regression fits.
For each solvent or reference solution condition, the viscometry functions were
plotted vs the polymer concentration for the Huggins treatment or the inverse concentration for the Wolf treatment, respectively per figure 3.2. Determination of the
∗
extrapolated linear intercepts and slopes were used to find the apparent [η]∗ and kH

according to equations (3.1), (3.7), and (3.8). To assess for the presence of shear
sensitivity on the intrinsic viscosity, determination of intrinsic viscosity at shear rates
of 2,500, 5,000, and 7,500 1/s were conducted for PVP in methanol solutions (figure
3.3). No meaningful effect of shear on [η] was observed by either analysis method; and
as such, only single shear rate measurements were conducted for remaining solutions.
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Figure 3.3: Intrinsic viscosities of PVPK25 in methanol measured at variable shear
rates of 2,500, 5,000, 7,500 1/s and evaluated by Wolf (M) and Huggins (◦) methods. No meaningful effect of shear is observed, demonstrating expected Newtonian
behavior of dilute PVP solutions for this study.
True [η] was then calculated from equation (3.9) to correct for preferential solvation effects observed in chapter 2 for the MeOH-ACE and MeOH-NAP systems.
Only apparent [η]∗ values are presented for the DCM-ACE systems due to lack of
preferential solvation parameters to correct for these conditions. Unfortunately, due
to the large relative error observed for the

d[η]
dθACE

terms, similar corrections to the

Huggins coefficient per equation (3.10) are not experimentally meaningful and thus
∗
only kH
is presented for all data sets. Summary DSV results can be seen in figures 3.4

and 3.5 for the MeOH systems and figures for the DCM systems. Tables 3.1 and 3.2
contain the numerical results and quantification of analytical differences by method
for the MeOH and DCM systems, respectively.
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∗
(•) vs θACE for PVP in MeOH-ACE
Figure 3.4: True Wolf [η] (◦) and apparent kH
and MeOH-NAP systems. M and N are results in the presence of 50 mg/mL NAP in
methanol. Trace lines are included as an aid to the eye. Error bars are 95% confidence
intervals.

∗
Figure 3.5: True Huggins [η] (◦) and apparent kH
(•) vs θACE for PVP in MeOH-ACE
and MeOH-NAP systems. M and N are results in the presence of 50 mg/mL NAP in
methanol for PVP in MeOH-ACE and MeOH-NAP systems. Trace lines are included
as an aid to the eye. Error bars are 95% confidence intervals.
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∗
Figure 3.6: Apparent Wolf [η]∗ (◦) and apparent kH
(•) vs θACE for PVP in DCMACE systems. Trace lines are included as an aid to the eye. Error bars are 95%
confidence intervals.
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∗
Figure 3.7: Apparent Huggins [η]∗ (◦) and apparent kH
(•) vs θACE for PVP in
DCM-ACE systems. Trace lines are included as an aid to the eye. Error bars are
95% confidence intervals.

In figures 3.4, 3.5, 3.6 and 3.7, it can be seen that both techniques produce similar
results and trends, with two important distinctions. First, it can be visually assessed
∗
are generally larger for the
that the 95% confidence intervals for both [η], [η]∗ and kH

Huggins treatment in comparison with the Wolf treatment across all systems. Second,
∗
it is also clear that the Huggins values for kH
demonstrate a greater variation with

respect to θACE , encompassing a range of values of 0.284-0.901 compared with 0.3300.560 for the Wolf data for the MeOH systems, while the DCM systems range from
0.167-1.039 compared with 0.107-0.732 for the Wolf data. Typically, it is expected
∗
that the kH
of flexible chains such as PVP should fall within 0.2-0.4 for good solvents

and within 0.4-0.7 for theta and poor solvents [158] - implying that the Wolf treatment
provides outcomes more consistent with theoretical expectations, even for these mixed
solvent and cosolute systems. Additionally, greater error is observed in the DCM
systems compared with the MeOH systems - this can be attributed to the 20-30%
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Table 3.1: Wolf vs. Huggins DSV Analysis for ACE/NAP-MeOH systems
Wolf
∗

±95%CI %ERR

Huggins
∗
kH

± 95%CI %ERR

±95%CI

%ERR

∗
kH

±95%CI

%ERR

%

(—)

(—)

%
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θACE

[η]

(v/v)

(dL/g)

(dL/g)

%

(—)

(—)

%

0.000

0.171

0.003

1.73

0.515

0.055

10.67

0.167

0.004

2.26

0.701

0.050

7.15

0.169

0.185

.002

1.28

0.390

0.039

10.10

0.182

0.008

4.55

0.503

0.089

17.72

0.250

0.208

0.004

2.13

0.330

0.059

17.87

0.202

0.013

6.18

0.424

0.118

27.78

0.314

0.185

0.003

1.65

0.365

0.052

14.28

0.194

0.017

8.91

0.284

0.199

70.04

0.440

0.169

0.007

4.19

0.479

0.104

21.69

0.163

0.011

7.06

0.716

0.152

21.24

0.500

0.191

0.005

2.51

0.376

0.076

20.32

0.189

0.008

3.98

0.437

0.089

20.34

0.550

0.168

0.006

3.40

0.463

0.110

23.79

0.165

0.009

5.20

0.603

0.114

18.85

0.647

0.151

0.005

3.29

0.560

0.091

16.31

0.144

0.009

6.12

0.901

0.153

16.97

0.733

0.164

0.006

3.63

0.408

0.093

22.89

0.159

0.011

6.84

0.553

0.144

26.00

0.810

0.153

0.003

1.95

0.455

0.069

15.12

0.154

0.007

4.31

0.513

0.103

20.07

0 w/ NAP

0.181

0.009

4.88

0.401

0.147

36.58

0.171

0.006

3.43

0.643

0.189

29.35

[η]∗

±95% CI %ERR

∗
kH

[η]

∗

(dL/g) (dL/g)

∗
[η] vs kH
[Rη ] vs RH

±95% CI %ERR

∗
kH
vs kD

0.003

-0.004

-2.56 -0.140

-0.046

-5.99

Wolf R2

0.620

0.752

0.071

∆(W − H)% 2.03

-40.1

-41.8

-31.8

-8.79

Huggins R2

0.582

0.569

0.019

∆(W − H)

-20.5

±95% CI are the 95% confidence intervals
%ERR values are the relative % errors of the 95% confidence intervals to the observed parameter estimates
∆(W − H) and ∆(W − H)% are the average difference and % average difference between the Wolf and Huggins treatments, respectively

lower relative viscosities of the DCM systems as these measurements are operating
nearer to the sensitivity limits of the rheometer.
Per the results of the MeOH (DCM) systems listed in table(s) 3.1 (3.2), the
Wolf method yielded 2 (3)% larger [η]∗ values relative to the Huggins with reduced
∗
absolute errors of ≈ 40 (57)%, while producing smaller kH
values by about 20 (46)%,

with exhibits greater internal consistency with a slightly higher linear correlation R2
∗
between [η]∗ and kH
of 0.620 (0.684) vs 0.582 (0.554), per the bottom right section

of the table . Importantly, the MeOH system Wolf results also align more closely
with the prior DLS results, with a sharp polymer collapse and loss of solvent quality
observed at 30% and >50% θACE , as indicated by a drop in the intrinsic viscosities
and rise in the Huggins coefficients, respectively. As such, it becomes apparent that
the Wolf method is the better technique for understanding the systems studied in
this work and offers support that it may be better suited for the study of other
multi-component systems in general.
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Table 3.2: Wolf vs. Huggins DSV Analysis for DCM systems
Wolf
∗

±95%CI %ERR

Huggins
∗
kH

± 95%CI %ERR

∗

∗
kH

±95%CI

82

[η]

(v/v)

(dL/g)

(dL/g)

%

(—)

(—)

%

%

(—)

(—)

%

0.000

0.175

0.008

4.53

0.243

0.159

65.43

0.172

0.012

6.75

0.285

0.188

66.03

0.114

0.179

.014

7.65

0.107

0.257

241.8

0.175

0.018

10.29

0.167

0.278

166.18

0.225

0.141

0.021

14.93

0.706

0.565

80.10

0.136

0.035

25.55

1.039

0.935

89.97

0.332

0.157

0.013

8.07

0.363

0.243

66.89

0.149

0.028

18.93

0.723

0.736

101.72

0.436

0.137

0.011

8.03

0.367

0.317

86.44

0.135

0.015

11.20

0.474

0.374

78.93

0.537

0.153

0.014

8.98

0.381

0.407

95.47

0.146

0.022

14.89

0.633

0.499

78.81

0.632

0.131

0.009

6.99

0.407

0.351

86.24

0.129

0.011

8.84

0.493

0.367

74.43

0.728

0.110

0.002

1.92

0.732

0.107

14.61

0.108

0.004

3.39

0.972

0.155

15.97

[η]∗

±95% CI %ERR

∗
kH

[η]

±95%CI

θACE

(dL/g) (dL/g)

%ERR

∗
[η] vs kH
[Rη ] vs RH

±95% CI %ERR

%ERR

∗
kH
vs kD

0.004

-0.007

-4.84

-0.185

-0.146

8.04

Wolf R2

0.684

N/A

N/A

∆(W − H)% 2.69

-57.5

-62.2

-46.3

-50.0

-0.466

Huggins R2

0.554

N/A

N/A

∆(W − H)

±95% CI are the 95% confidence intervals
%ERR values are the relative % errors of the 95% confidence intervals to the observed parameter estimates
∆(W − H) and ∆(W − H)% are the average difference and % average difference between the Wolf and Huggins treatments, respectively

Figure 3.8: RH (◦) and Rη (•) vs θACE . M and N are results in the presence of
50 mg/mL NAP in methanol. Viscometric radii demonstrate similar behavior to
hydrodynamic radii, though on average ≈ 28% smaller in value. Trace lines are
included as an aid to the eye. Error bars are 95% confidence intervals.
When we next compare the MeOH DSV results to the DLS outcomes from chapter
2, the Wolf treatment also correlates more strongly with respect to both the hydrodynamic (RH ) and viscometric radii (Rη ), as well as between the DLS interaction
∗
). It is worth noting how
parameter (kD ) and the apparent Huggins coefficient (kH

well the MeOH DSV behavior captured in figures 3.4 and mirrors the DLS outcomes
presented in figures 2.3 and 2.4. [η] demonstrates swelling of the polymer coils up
to 25% acetone fraction, then contracting at 30% before swelling again near 40-50%,
with further polymer collapse upon increasing acetone; with consistent inverse be∗
havior observed for kH
. Similar trending behavior is observed when comparing the

RH with Rη , though increased error in Rη is observed due to uncertainty in the Mw
determination (figre 3.8). No difference is observed in [η] in the presence vs absence
of co-dissolved naproxen, just as no difference was observed in RH for the same. Notably, an apparent minor improvement in solvent quality is observed in the presence
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∗
of the drug cosolute with respect to kH
- though the difference with respect to the

pure methanol solution is not statistically significant. In contrast, kD was able to
distinguish a significant loss of solvent quality when in the presence of drug, and it
was similarly found to be preferentially excluded by SLS techniques. This disagree∗
ment may be due to the inability to correct kH
for preferential solvation effects due

to limitations in sensitivity of the rheometer. Taken together, the MeOH DSV and
light scattering are in good agreement and tell a story of non-obvious complex polymer behavior in the methanol-acetone and methanol-naproxen systems; though light
scattering may be more sensitive to solvent quality changes for these systems.
Interestingly, the DCM systems appear to exhibit more predictable behavior in
comparison to the MeOH systems, with steadily decreasing [η]∗ as θACE increases
until precipitation was observed. There does not appear to be strong instances of
out of trend behavior as for the MeOH systems as observed with swelling at 25% and
40-50% acetone content. It is unfortunate that light scattering data was unable to
be completed for the DCM systems, as the strong background scattering of the DCM
solvent precluded the generation of high quality light scattering data at this time.
Should the absence of strong preferential solvation effects be found in the DCM systems, this may help bolster the argument that such effects are responsible for the out
of trend swelling behaviors found in the MeOH systems, as they correlate well with
λ. For the most part, PVP appears to be in a more collapsed state in the DCM system as indicated by the generally smaller [η]∗ values measured at comparable acetone
content. This suggests that DCM is not as capable of over coming the poor ACEPVP interactions as MeOH may be for PVP and/or that DCM-ACE interactions are
relatively stronger than for MeOH-ACE such that the polymer is excluded from those
solvents. Per [15], the DCM-ACE systems demonstrated improved physical stability
of NAP-PVP dispersions relative to those prepared out of MeOH-ACE systems. From
these perspectives, we may speculate the possibility that strong DCM-ACE interactions may similarly exclude naproxen, such that polymer-drug interactions are more
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favorable overall, which may then lead to more homogeneous dispersions.
3.5

Conclusions

In this chapter we have evaluated the Wolf method against traditional Huggins treatments for DSV data across a range of mixed cosolvent/cosolute compositions for
PVPK25 solutions. The wolf method was found to be superior compared to the
Huggins approach in terms of both relative and absolute errors while demonstrating
greater internal consistency across all systems studied. The results from the Wolf
method also correlated most strongly with the prior light scattering results explored
in chapter 2, further supporting its likely greater accuracy and precision. We conclude that the wolf method is the preferred tool for the analysis of DSV data of mixed
cosolvent/cosolute systems.
The DCM system exhibited more predictable behavior in comparison to the MeOH
systems with increasing acetone content, as the polymer steadily collapsed in size as
the precipitation point was reached near 82% acetone content. MeOH appears to
mitigate the loss in solvent quality better than DCM for PVP with added acetone,
as demonstrated by larger polymer size at similar acetone levels. The DCM data was
more variable and less precise than the MeOH system, attributed to lower absolute
viscosities measured near the sensitivity limits of the rheometer. Overall, the MeOH
system viscometry data agreed well with the light scattering data from chapter 2,
with the polymer swelling and increasing in size at the same acetone concentrations
as identified by DLS results. Importantly however, the presence of naproxen was not
found to have an impact on the DSV results in comparison to its absence - highlighting
light scattering as a potentially more sensitive and useful technique for understanding
drug-polymer interactions and/or the need for a more sensitive rheometer.
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3.6

Future Work

Quantifying of drug-polymer-solvent thermodynamic parameters by viscometry
An understanding of drug-polymer-solvent interactions is often desired when studying
amorphous dispersions, with important applications to both the solution and solidstate as previously discussed. In particular to spray dry processing, knowledge of all
binary and ternary Flory-Huggins (FH) interaction parameters in solution would be
ideal, though these parameters are often experimentally difficult to determine using
classical approaches such as static light scattering, osmometry, refractive index, or
head-space gas chromatography. These methods typically necessitate highly specialized knowledge and training, expensive instrumentation, tedious sampling requirements, and/or substantial material quantities. In contrast, alternative viscometric
techniques are generally simple to perform and interpret, and can be executed with
inexpensive equipment using relatively small sample sizes. Notably, glass viscometers offer little control over shear effects and can be quite tedious in practice, though
modern instrumentation exists which are available at moderate costs (such as the
Rheosense microVisc utilized in this work) to address most of these concerns.
Analytically, the connections between viscometry and FH interaction parameters
have been mostly solved, though they are little appreciated or applied in the field
of spray dried dispersions. Approximately 40 years ago, Kok and Rudin developed
a method to relate intrinsic viscosity measurements to second virial coefficients and
polymer-solvent FH interaction parameters[]. However, a major limitation of their
approach is knowledge of the intrinsic viscosity of the polymer under theta solvent
conditions which can add substantial experimentation if this parameter is unknown.
This value can be determined using either the classical Mark-Houwink method using several fractions of varying molecular weight polymer or through the Gundiah
and Kapur method, by measuring the intrinsic viscosity with increasing anti-solvent
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content until the polymer phase separates, and then extrapolating [η] with respect
to the antisolvent composition to the observed precipitation point as [η]θ [159, 160].
If the Mw of the polymer and the Mark-Houwink constant at theta conditions Kθ
are already known, then [η]θ can be easily calculated []. Unfortunately, these parameters are often unknown or unavailable to many pharmaceutical practitioners.
Qian et al developed an analytical method to estimate [η]θ from the intrinsic viscosity determined at a typical non-theta condition [161], though is reliability and
veracity has been questioned [162]. Lastly, Xu and Qiu utilized cloud points extracted from simple titration measurements in combination with groups of candidate
antisolvent-polymer and solvent-antisolvent interaction parameters derived from viscometric measurements, which were then best fit to the observed binodal curves for
the accurate determination of all ternary FH interaction parameters. It is quite possible that this same approach will be applicable to drug-polymer-solvent systems and
is worth further investigation.
With reliable knowledge of the theta and non-theta intrinsic viscosities, second
virial coefficients and the ternary system FH parameters, a range of critical material
properties can be explored in spray dried dispersions. For example, the polymer membrane literature is well aware of the relationship of the strength and compositional
dependence of the solvent-cosolvent interaction parameter and resulting varieties of
microstructures that develop during precipitation events. Specifically, as the polymersolvent and/or polymer-cosolvent interaction parameters increase in favorability, the
expected miscibility gap during concentration reduces and larger macrovoid structures
are expected to form; in contrast where solvent-cosolvent interactions are increasing
in favorability, then a more porous sponge-like structure is expected as the miscibility
gap increases with precipitation [163]. This offers the opportunity to engineer SDD
microstructures by varying solvent and drug solute compositions in spray drying processes which can affect properties such as particle density and surface area available
to enhance dissolution performance. Additionally, and most strongly relevant to the
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prior light scattering work in this dissertation, Campos et al derived a relationship between the FH interaction parameters and the inversion point for preferential solvation
- that is the cosolvent and/or drug concentration in the feed solution the controls its
preference for residing with or external to the pervaded volume of the polymer [164].
This knowledge allows the formulator to potentially tailor the extent of local interactions in solution prior to forming the spray dried dispersion using relatively simple
measurements. Clearly the opportunities for leveraging viscometric approaches in
SDDs is a rich environment ripe for further investigation.
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CHAPTER 4: EFFECT OF FORM AND ENVIRONMENTAL MOISTURE ON
THE HYDROLYTIC STABILITY OF A HP-API IN A CONTROLLEDRELEASE WET GRANULATION

4.1

Introduction

The United States continues to battle an opioid epidemic that has been so costly, in
terms of both human lives and dollars, that it was declared a public health emergency
in 2017 [165, 166, 167, 168]. The onset of the epidemic is generally attributed to
the over prescription of opioids beginning in the 1990s, eventually giving way to
increasing utilization of illicit heroin and fentanyl by the early 2010s and leading to
the widespread prevalence of overdose deaths and addiction (i.e. opioid use disorder
(OUD)) [169, 168]. At its 2017 peak, the crisis resulted in the loss of more than
47,000 lives and 2.3 million cases of OUD [170]. Federally funded research studies
into comprehensive community approaches to curb overdose death rates have recently
been initiated; however, significant work remains to understand and apply effective
treatment strategies on a national scale.
As these efforts continue, it is critical that practitioners and patients have options
to navigate the environmental, behavioral, and physiological factors that can influence
recovery treatment success. One such physiological factor that can create barriers
to initiating recovery treatment is opioid withdrawal syndrome (OWS) [171, 172,
173]. OWS manifests as a constellation of intense flu-like symptoms including nausea,
vomiting, diarrhea, sweating, rhinorrhea, lacrimation, and muscle cramps as well
as anxiety and insomnia [174, 175]. When not adequately treated, the intensity of
withdrawal symptoms can drive patients to return to opioid use [176, 177].
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Pharmacological intervention for OWS occurs with two primary drug classes, opioid agonists and α2-adrenergic agonists. Medications in the α2 agonist class for OWS,
primarily clonidine and lofexidine, are the favored management strategy for patients
and communities with preferences or contraindications that limit the therapeutic use
of opioid agonists. Additional pharmacodynamic effects resulting from this mechanism of action include reduced blood pressure (consistent with clonidine indicated
uses) and heart rate, somnolence, and dry mouth [178]. Comparative trials of lofexidine and clonidine, summarized in a Cochrane review, generally concluded that the
agents were equally effective but that lofexidine was associated with better tolerability [179, 180, 181, 182]. Lofexidine has been approved in the United Kingdom (U.K.)
since the 1990s, and recently gained US FDA approval for the treatment of OWS in
2018 as an immediate release (IR) branded product, LUCEMYRA™ [183, 184].
LUCEMYRA is a highly potent compound and is currently dosed as a 0.18 mg
lofexidine (0.2 mg HCl salt) tablet that is usually administered as 3-4 tablets (0.525
to 0.700 mg) QID (i.e. four times daily) for up to 14 days. Although the QID
regimen does support successful treatment, the requirement for such frequent administration is not ideal, particularly given the labeled opportunity for the outpatient
use of LUCEMYRA. Adherence to the lofexidine dosing regimen is important to
maintain exposures associated with efficacy as missed doses and the resulting subtherapeutic exposure in the opioid-withdrawing patient can have significant consequences. Several studies have demonstrated significant improvement in patient compliance/adherence for prescribed medications when fewer daily doses are required in
the outpatient setting [185, 186, 187, 188, 189]. Modified or controlled-release systems are commonly employed solutions which offer multiple clinical benefits including
modification of pharmacokinetic (PK) parameters, enhanced control of pharmacokinetic/pharmacodynamic (PK/PD) effects, and reduction of dosing frequency. As
such, the development of an extended release (XR) lofexidine tablet was initiated
to reduce patient pill burden and explore opportunities to improve adherence and

90

PK/PD effects.
Lofexidine contains a 2-imidazoline ring which is generally understood to be susceptible to alkaline hydrolysis via a specific base catalysis ring opening mechanism
[190, 191, 192, 193]. However, the rate of degradation is much reduced under neutral
and mildly acidic conditions. As such, citric acid was utilized in both the IR and XR
formulations to act as an organic acid stabilizer to facilitate a reduced solid-state pH.
However, during the development of the XR product, increased degradation due to
hydrolysis was observed relative to the IR formulation despite prior successful application of the citric acid stabilizer. This necessitated reformulation investigations to
understand and improve the stability of the XR product.
The XR formulation utilizes a wet granulation process to ensure adequate uniformity of the low dose API within the final blend. The acid and API are both
dissolved in ethanol which is then sprayed into the granulation powder bed to distribute the acid and API in intimate contact to control the local pH. A consequence
of this approach is that the co-dissolved API and acid may precipitate in a variety of
physical states including amorphous, co-crystal(s), hydrates, solvates, and/or polymorphic forms which will likewise exhibit a range of chemical stability and moisture
sensitivity. For example, amorphous materials are well known to be more chemically
reactive while also sorbing excess moisture relative to crystalline forms [194].
As such, the purpose of this study is to characterize the presence/absence of the
API crystalline or amorphous form, moisture sensitivity, and chemical stability under
a variety of temperature and relative humidity conditions using several organic acid
stabilizers at varying amounts to identify a reformulation which exhibits acceptable
stability performance. It is hypothesized that the organic acid conditions which allow
the API to precipitate as a stable crystal after wet granulation and exhibit low pKa(s)
and hygroscopicity will be best suited to ensuring a stable and robust formulation.
The effects of temperature and environmental moisture on degradation rates will be
assessed through a modified Arrhenius equation to better elucidate differences in acid
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formulations. Additionally, we aim to propose a formulation strategy for continued
development that is able to prevent 3% formation of the hydrolysis product over the
course of a projected two year shelf life at 25 °C / 60 %RH.
4.2

Background

Imidazoline hydrolysis
Literature review of imidazoline hydrolysis indicates that under basic media, the rate
of reaction is expected to be greatest when the neutral form approaches its maximum
and demonstrates an apparent 1st order reaction with respect to the hydroxide ion as
pH increases beyond this point [195, 193]. Alkaline hydrolysis has been found to be
first order with respect to both hydroxide and imidazoline concentrations, and overall
is a bimolecular second-order reaction [191]. The evidence appears to favor that the
rate determining step in basic media (where the protonated form is negligible) is due
to the attack of the hydroxide ion on the neutral molecule at the imine carbon, though
there is some argument that the ring opening step may be the rate limiting step as
well [191, 195, 193]. Steric hindrance at the α-carbon has been shown to substantially
reduce hydrolysis rates in basic media [195] supporting the hydroxide attack as rate
limiting. As pH increases such that the fraction of protonated form is minuscule,
ring-opening would become the rate limiting step as protonation is likely required to
facilitate the amine as a stable leaving group. Overall, the literature supports the
hydroxide ion attack on the neutral form as the rate limiting step in strongly basic
media.
In a study of antazoline hydrolysis, a distinct mechanism in semi-alkaline media
(pH 6.0-7.4) with a slower rate limiting step attributed to attack by the hydroxide
ion at the α-carbon on the protonated form, when compared to the neutral molecule
[193]. This is consistent with work done on imidazolines by S.O. Bondareva et al
where the protonated form is associated with reduced hydrolysis rates observed for
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pH ≈ 6-10 which was attributed to a reduction in the partial positive at the α-carbon
thereby destabilizing the carbo-cation resonance form with the imine nitrogen [195].
This demonstrates the protective effects of increasingly acidic media on hydrolysis
when the rate limiting step is attributed to nucleophilic attack at the α-carbon. For
pH near 5, antazoline was found to demonstrate a non-catalyzed mechanism with a
proposed rate limiting step attributed due to the ring opening step and had the lowest
degradation rates observed from pH 0-7.4 (i.e. pH of maximum stability), [193]. At
pH 3-4, antazoline was found to exhibit an increased rate of hydrolysis relative to pH
5 and the rate limiting step was now attributed to the nucleophilic attack of water
on the protonated molecule. The ring opening step is no longer rate limiting as the
protonated amine consistently behaves as a strong leaving group [193]. This implies
the possibility of an optimal pH to inhibit hydrolysis of some imidazolines rather
than simply always increasing the acidity. Under acidic media, the rates of hydrolysis
for imidazolines are found to be substantially reduced relative to basic conditions
[191, 195], consistent with our internal results.
Notably, there are much less studies exploring the degradation mechanism and
kinetics under acidic conditions. S.O. Bondareva et al. argued that in acidic conditions, the rate is expected to be greatest when both protonated forms of the imine and
secondary amine within the ring are at their maximum, as this allows for the development of a partial positive charge at the α-carbon [195], though this is not supported
across the remaining literature observed. Similar to basic conditions, the rate limiting
step is proposed to be the attack of water at the α-carbon, though there is little direct
evidence to support this assumption [191, 195]. This is expected to be most prevalent
at strongly acidic conditions, i.e. < 2 pH [191, 195]. In contrast, K. Berzins et al
found that additional complex mechanisms of hydrolysis with additional intermediates and increased rates were observed under highly acidic conditions for antazoline
[193]. A study by S. Limatibul and J.W. Watson on the degradation kinetics of 2(m-Nitrophenyl)-imidazoline under highly acidic conditions found increasing rates of
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hydrolysis under increasing molarity of H2SO4 from 4-14 molarity. The rate limiting
step is again attributed to nucleophilic attack by water at the α-carbon, though attenuation of the rate kinetics was observed and attributed to reducing water activity
with increasing acid molarity [196].
A review of the literature was unable to unearth much evidence regarding the
specific vs. general catalysis behavior of imidazoline hydrolysis. S. Limatibul and
J.W. Watson did note that acid type can affect rates of hydrolysis in highly acidic
media with sulfuric and hydrochloric acids being ≈ 3x greater than perchloric acid
[196], though these environments may not be relevant to mild solid-state conditions.
Notably, LADP is an amide that is known to hydrolyze further to LDPA, and amides
are known to exhibit general catalysis indicating that buffer may influence LDPA
formation rates [197]. D. Drake et al demonstrated that amides undergo general acid
and base catalysis in the decomposition step after hydroxide ion or water attack at the
α-carbon through stabilization of the charged intermediate [198]. Aside from amide
hydrolysis, elucidation of the specific vs. general catalysis of imidazolines was unable
to be found in the literature and is likely worthy of future investigation. Likewise, no
studies on the stability of imidazolines in organic solvents were found.
Degradation modeling
It is often difficult to identify a suitable reaction mechanism for modeling purposes
in drug product degradation owing to a myriad of complexities that can be introduced due to the presence of multiple phases, crystal habit, surface area, excipient
interactions, and more [194]; in addition to the incomplete understanding of the solution state hydrolysis of LFX previously discussed. As such, stability studies are
executed with degradation behavior modeled empirically by fitting determining the
rate constant at initial conditions. Per ICH Q1E, evaluation of stability data guidance, shelf life estimations can be extrapolated from the observed linear degradation
rate to the maximum potency loss &/or degradant limits. ICH Q1A (R2) stability
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guidelines allow no more than a 5% change in drug potency within the shelf life of a
drug product [199]. This approach generally yields a reliable and conservative shelf
life as degradation rates are typically expected to be at their highest at initial conditions. In particular for the lofexidine tablet, the maximum acceptable upper limit of
the first hydrolysis degradant product has been previously established to be 3%, and
hydrolysis is the primary mode of degradation of the API.
With the initial rate constants determined at multiple temperatures and humidity
conditions, a greater understanding of the hydrolysis behavior can be explored with
the linear form of the humidity-corrected Arrhenius expression below [200]:
ln(k) = ln(A) −

Ea
+ B ∗ RH
RT

(4.1)

Where k is the initial linear rate constant in %/day, A the pre-exponential factor in
%/day, Ea the energy of activation in kJ/mol, R the gas constant in kJ/(mol*K), T
is temperature in Kelvin, B represents the moisture sensitivity factor, and RH is the
% relative humidity.
The pre-exponential or frequency factor, A, can generally be understood as an
empirically defined entropic component of the rate function, which reflects the frequency of molecular collisions which contribute to the reaction [201]. It is expected to
exhibit a weak relationship with temperature which is typically overshadowed by the
temperature effects of the exponential activation energy term in addition to the long
extrapolation to 0 K temperature such that A is often difficult to assess accurately.
A can be determined theoretically from collision theory and then be compared from
the empirical result for a qualitative interpretation of the empirical results. Lower
empirical results than collision theory indicates the potential for geometric or steric
constraints that hinder reaction progression while larger values imply strongly favorable entropic contributions [201]. The Ea term may be considered a measure of
thermal sensitivity of the reaction rate - the larger the activation energy, the less
sensitive the rate is to changes in temperature and vice versa. At higher Ea , a larger
thermal energy is required to overcome the barrier to reaction progression and as
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such the rate will slow down. Similarly, the B parameter represents sensitivity of
the reaction to water activity, where larger values indicate greater reactivity with
water. This parameter might be interpreted as the ability of the reactive substrate
to encourage or hinder interactions with water.
4.3

Materials and Methods

API, lofexidine hydrochloride (LFX), was provided by US WorldMeds, LLC (USWM,
Louisville, KY). Organic acid stabilizers comprising DL-malic (Alfa Aesar, Ward Hill,
MA), glutaric (Acros Organics, Fair Lawn, NJ), monohydrate citric, anhydrous citric,
tartaric, maleic, fumaric, oxalic, and adipic (TCI America, Portland, OR) acids were
purchased through VWR International (Radnor, PA). Succinic and pimelic acids were
purchased from Sigma-Aldrich (St. Louis, MO). Chemical structures of organic acids
and API are captured in figure 4.1.
Hydroxypropylmethylcellulose (HPMC K200) was used as the controlled release
polymer (CR) and ordered from XXX. Microcrystalline cellulose (MCC 50µm) was
used as both the intra-granular diluent and extra-granular binder, calcium stearate
(CaSt) as the lubricant, and povidone (PVP, Mw ≈ 40 kDa ) as the intra-granular
binder, were all purchased from Sigma Aldrich.
HPLC grade methanol, ethanol, acetonitrile, sodium phosphate, and 85% phosphoric acid were purchased from VWR International and used as received. 0.2 µm
hydrophobic PTFE syringe filters were sourced from Tisch Scientific (Northbend, OH)
and purchased though VWR International. All materials were used as received. Ultra
pure water was freshly prepared from a MilliQ XXX system and passed through a 0.2
um filter.
Film Preparation
Films were produced by first mixing LFX with the organic acids at a 1:1.13 (w/w)
ratio per the initial formulation composition, with 150 mg of LFX and 170 mg of
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(a) Adipic Acid

(b) Citric Acid

(c) Fumaric Acid

(d) Glutaric Acid

(e) Maleic Acid

(f ) Malic Acid

(g) Oxalic Acid

(h) Pimelic Acid

(i) Succinic Acid

(j) Tartaric Acid

(k) Lofexidine HCl

(l) Hydrolysis Product 1 (LADP
HCl)

Figure 4.1: Structures of organic acids, LFX, and hydrolysis product, LADP

acid. This was followed by dissolving the mixture in either ethanol or water with
approximately 5 minutes of sonication. The solution was then placed under a gentle
nitrogen stream at room temperature, evaporating the solvent to produce a film; this
process ranged from 24-48 hours. The films were then characterized by a combination of differential scanning calorimetry (DSC), dynamic vapor sorption (DVS), and
powder X-ray diffraction (XRD).
X-Ray Diffraction
Samples of 5-10 mg were placed on a low mass mirrored sample plate before being
compressed into a flat horizontal plane. Once planar, the sample was then transferred
to a mini flex powder x-ray diffractometer sample chamber (Rigaku Americas Corporation, TX, USA). Scanning was performed between 2-40°2θ using Cu Kα radiation
at 45 kV and 40 mA. The step size was set to 0.025°at a scanning speed of 1.00°min.
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Differential Scanning Calorimetry
Samples of 5-10 mg were placed within a T-Zero pan and hermetically sealed. The lid
was punctured, creating a pinhole to allow for evaporation of residual vapors. Once
sealed, the samples were transferred to a Q2000 DSC (TA Instruments, New Castle,
DE). All samples were evaluated with the DSC operating in ramp mode, equilibrated
first at 0°C before heating at a rate of 10°C/min up to 250°C. Reported thermal values
were determined from the resultant heat flow curves vs. temperature thermograms.
Dynamic Vapor Sorption
Moisture sorption isotherms were generated from dynamic vapor sorption (DVS) data
acquired from a Resolution instrument (Surface Measurement Systems, Allentown,
PA). Film samples were placed within the DVS sample chamber and dried at 40°C
and 0% relative humidity (RH) for 40 hours, then thermally equilibrated at 25°C and
0% RH for four hours, then the sample was held until the percent mass change of the
sample was equal to or less than 0.002% for a period of at least 5 minutes. Once this
criterion was met, % RH was increased in step sizes of 10% RH up to 90% RH, and
then back down from 90% RH to 0% RH. At each step, the sample was held until the
mass stability criteria of percent mass changes equal or less than 0.002% for 2 minutes
was met, or a period of four hours had elapsed - whichever occurred first. Total dry
nitrogen gas flow rates used to ensure % RH was 200 sccm. Equilibrium moisture
content was determined from the initial dry sample mass and the final sample mass
weights from each step condition.
Formulation & Process
Formulations were prepared according to the materials and process flow chart in figure
4.2. Granulation solutions were prepared at room temperature with a stir bar spinning
at 200 rpm until fully dissolved. The relative amount of dissolved solids were varied
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from ≈ 18-30% as necessary to ensure complete dissolution of the organic acids,
as they exhibited a large range of solubility in ethanol. Primary granulations were
prepared with mortar and pestle while slowly spraying the granulation solution from
a syringe onto the pre-mixed powder bed. The granulation solution container was
rinsed with an additional 5 mL of ethanol which was then added to the granulation
to aid in the recovery of any residual API from the container. The wet granulation
was wet-milled and dried in a vacuum oven at 40°C for two hours, then dry-milled.
Percent mass loss on drying (%LOD) after drying was found to be less than 5% for all
primary granulations. Diluent/binder was added along with the primary granulation
into a 0.5L media bottle which was then blended on a Turbula blender (Glen Mills
Inc, Clifton, NJ) for 5 minutes, resulting in the pre-blend. Lubricant was then added
and blended for an additional 1 minute on the Turbula to complete the final blend.
The intragranular MCC diluent amount was adjusted as necessary to account for
variation in the intragranular acid content. These adjusted amounts are called out at
their respective locations within figure 4.2. The initial acid screening stability study
included all 10 acids at 0.565 (1x) total w/w % (8.54 % intragranular MCC), while
the second stability study only included the top 5 performing acids at 10 times the
increased amount at 5.654 (10x) total w/w % (3.45 % intragranular MCC).
Stability Study
Initial stability screening was conducted by preparation of all acid formulations at
0.565 w/w % which were placed in open 20 mL vials and stored at conditions of 58%
RH at 25°C, controlled by placing the vials within a sealed glass desiccator containing a saturated salt solution of sodium bromide stored in an incubator set to 25°C.
After two weeks, the powders in the vials were mixed with a spatula to ensure homogeneity before sampling for solid-phase extraction (SPE) and HPLC analysis. The
bottom five performing acids were removed from further study and the remaining
acids were evaluated at additional times points and storage conditions of 43% RH,
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25°C (potassium carbonate salt solution, KCO3) and 75% RH, 40°C (sodium chloride
salt solution, NaCl) to further explore moisture and temperature stability. Formulations of the top five performing acids were prepared at higher acid concentrations of
5.654 w/w % to assess the effects of increased acid amounts on stability and analyzed
at one and two weeks after exposure to conditions of 75% RH, 40°C (i.e saturated
NaCl solution).
High Pressure Liquid Chromatography
HPLC analyses were conducted on a Dionex Ultimate 3000 HPLC System (Thermo
Scientific, Waltham ,MA) with degasser, binary pump, autosampler set to 4°C, column oven set to 30°C, and UV detector set to a detection wavelength of 214 nm.
Separation was achieved with a Waters Sunfire C18 Column (250 mm length, 4.6
mm diameter, 5 um particle size) and Phenomenex KrudKatcher Ultra In-Line Filter
(0.5 um x 0.004 in.) using a gradient with mobile phase A consisting of a mixture of
acetonitrile (MeCN) and 0.06 M KH2 P O4 buffer (20:80 v/v), pH 3.0 (adjusted with
85% phosphoric acid), and mobile phase B consisting of pure MeCN, as captured in
Table 4.1. SPE of samples was conducted by weighing out 50 mg formulation powder
into 5 mL of methanol, which was vortexed for 30 seconds, sonicated for 5 minutes,
then vortexed for an additional 30 seconds. Samples were then centrifuged at 13k
RPM for 10 minutes. The supernatant was filtered and diluted 5x with mobile phase
A into an HPLC vial to a target LFX concentration of 20 µg/mL, and stored at 4°C
until analysis. The assay results are reported with respect to the % LADP formation
relative to the remaining LFX, taken as the ratio of the peak areas after adjusting
for the relative response factor of 0.778 for LADP/LFX as previously established by
USWM (data not shown). No unknown peaks were observed in this course of this
study.
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Figure 4.2: Materials and process flow chart of the wet granulated controlled-release
lofexidine formulations
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Table 4.1: HPLC Gradient Method
Time (minutes)

% Mobile Phase A

% Mobile Phase B

0.0

100

0

7.0

100

0

30.0

56

44

35.0

56

44

45.0

100

0

Data Analysis and Presentation
Chemical structure figures were prepared in ChemDraw Professional, version 19.1.1.21
(PerkinElmer, Waltham, MA). DVS and XRD graphs and formulation stability statistical analysis were prepared in Microsoft Excel for Microsoft 365 32-bit (Microsoft,
Redmond, WA) with visualization aided by Daniel’s XL Toolbox addin for Excel, version 7.3.2 [138]. DSC figures were prepared in Thermal Advantage Software version
5.5.24 (TA Instruments, New Castle, DE). All errors presented are 95% confidence
intervals as determined by regression analysis unless stated otherwise. OPLS multivariate analysis was conducted using SIMCA 16 (Sartorius Stedim Data Analytics
AB, Umeå, Sweden)
4.4

Results and Discussion

Solid-State Characterization
In order to understand the solid-state behavior of the organic acid-LFX films prepared
out of ethanol, it is necessary to compile and develop an overall picture of the data as
extracted from the various XRD, DSC, and DVS techniques. It is also worth noting
that each film was also visually assessed for opacity or clarity. Samples which are
opaque imply the presence of crystalline forms while clear samples indicate a glassy,
isotropic phase. All films were found to be opaque with the exception of the citric
acid film, indicating the formation of a glass between the drug and citric acid, and
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crystalline forms in all other cases. In agreement with the visual observations, all films
are found to be crystalline by XRD per the observation of sharp peaks characteristic
of ordered structures in crystalline materials, with the exception of the citric acid
film which exhibits the unmistakable amorphous ‘halo’ consistent with amorphous
forms per figure 4.3. For the crystallized films (panels c & d), the presence of new
peaks or loss of previous peaks at θ values relative to those observed in the initial
pure components (panels a & b) implies the potential for new polymorphic, salt, &/or
co-crystal forms. Those films which appear to potentially exhibit new forms due to
the presence of additional or loss of prior peaks include the fumaric, maleic, oxalic
and tartaric films. The remaining crystalline films, adipic, glutaric, malic, pimelic
and succinic appear to indicate a mixture of the initial acid and API forms rather
than new structures.

(a) As Received LFX-HCl, Adipic, Citric (monohydrate,
anhydrous), Fumaric, & Glutaric acids

(b) As Received LFX-HCl, Maleic, Malic, Oxalic,
Pimelic, Succinic, & Tartaric acids

(c) Ethanolic films of pure LFX-HCl & LFX-Acid
mixtures (Adipic, Citric, Fumaric, Glutaric, & Maleic
acids)

(d) Ethanolic films of pure LFX-HCl & LFX-Acid
mixtures (Malic, Oxalic, Pimelic, Succinic, & Tartaric
acids)

Figure 4.3: X-ray diffractograms of API and Organic acids: As received (a, b) and
film precipitates out of ethanolic solutions (c,d). Notably, all films exhibit crystalline
behavior with the exception of the amorphous ‘halo’ observed for the LFX-CA film.
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The DSC data can describe the presence of crystalline and/or amorphous forms
through the observation of glass transition temperatures and enthalpic melting events.
Per figure 4.4, parts a) and b) we can observe the summary DSC thermograms of the
as-received organic acids and API for comparison to the DSC results for the films
in parts c) and d). The majority of the as-received acids as well as the API all
demonstrate a pronounced sharp endothermic event which indicates their respective
melting points, and some broad deviations from the baseline following the melt, that
can generally be attributed to the onset of chemical degradation experienced within
the range of the temperature scan of the DSC experiments; all of which agree well with
the literature. A more detailed review of the as-received DSC data follows for those
acids which exhibit more complex behavior (i.e. citric, fumaric, glutaric, pimelic, and
oxalic acids).
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(a) As Received LFX-HCl, Adipic, Citric
(monohydrate), Fumaric, Glutaric & Maleic acids

(b) As Received LFX-HCl, Malic, Oxalic, Pimelic,
Succinic, & Tartaric acids

(c) Ethanolic films of pure LFX-HCl & LFX-Acid
mixtures (Adipic, Citric, Fumaric, Glutaric, & Maleic
acids)

(d) Ethanolic films of pure LFX-HCl & LFX-Acid
mixtures (Malic, Oxalic, Pimelic, Succinic, & Tartaric
acids)

Figure 4.4: DSC thermograms of LFX and organic acids: As received (a, b) and film
precipitates out of ethanolic solutions (c,d).
Per the as received citric acid monohydrate thermogram in 4.4 part a), we can
see a series of endothermic events which indicate various phenomena with respect
to temperature. The first event beginning at ≈

37 °C up to 100 °C represents

the dehydration of the monohydrate form (sharp peak) and evaporation of entrained
moisture (broad slope) as it converts to the anhydrous form [202], which then melts
per the sharp peak near ≈ 152 °C [203], before the onset of chemical degradation
(broad hill) at ≈ 175 °C and higher temperatures [204]. Notably, as fumaric acid
melts at temperatures higher than those explored in this study, no strong melting
event is observed, though a small endothermic event near 205 °C is observed that is due
to a polymorphic transition [205]. Glutaric acid has a minor endothermic peak prior
to its primary melting point, which is attributed to the polymorphic conversion from
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the room temperature stable β form to the α form which is more stable at elevated
temperatures [205]. In panel b) we can observe that pimelic acid has two small
endothermic events prior to its expected melting point which are likewise attributed
to polymorphic transitions of form 3 → 2 → 1, with its melting point observed near
104 °C [206]. The as-received oxalic acid was in a dihydrate from and as such its
behavior is most similar to that observed in the monohydrate citric acid, though with
an additional exothermic peak observed between the dehydration event and melting
temperature which can be attributed to crystallization into the stable form before
melting [207].
When reviewing panels c) and d), the films behave in substantially different ways
than the as received materials and can be partitioned into three groups of outcomes.
The first group of films (containing adipic, glutaric, pimelic, and succinic acids) are
those which exhibit essentially single endothermic peaks (either sharp, broad, or shallow) that occur below the melting points of both the initial acid and API forms and
are characteristic of a eutectic melting process [205]. The films imply that forms similar to the as-received materials exists after precipitation out of ethanol. In the second
group (fumaric, maleic, malic, oxalic, and tartaric acids), either single, broad/shallow
and or multiple endothermic events are observed, with or without additional exothermic events that occur after the endothermic peaks which together indicate the possible
formation of salts &/or co-crystals consisting of both the acid and API [205]. Lastly,
the third group contains only the citric acid film, which displayed a glass transition
near 100 °C and a small endothermic event near 175 °C. Due to the visually transparent nature of this film and the glass transition event, we can be confident that the
majority of this sample is in the amorphous state and distinct from all other films.
This is an important finding as amorphous materials tend to be more chemically reactive and sorb excess moisture relative to crystal forms [194], which may exacerbate
the hydrolysis of the API. Overall, the DSC data agrees well with the XRD results
with the possible exception of the malic acid film, which has greater ambiguity as
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to whether a new form is present or not. The DSC results indicate large potential
variability in the API form after precipitation, including possible salt/co-crystal formation with the acids in group 1, preservation of the initial crystal form with acids
in group 2, and stabilization in the amorphous state with citric acid.

(a) Example DVS Isotherm for LFX-GA film.

(b) As Received LFX-HCl, Maleic, Malic, Oxalic,
Pimelic, Succinic, & Tartaric acids

(c) Ethanolic films of pure LFX-HCl & LFX-Acid
mixtures (Adipic, Citric, Fumaric, Glutaric, & Maleic
acids)

(d) Ethanolic films of pure LFX-HCl & LFX-Acid
mixtures (Malic, Oxalic, Pimelic, Succinic, & Tartaric
acids)

Figure 4.5: Example LFX-GA DVS isotherm (a) and summary DVS results of
hygroscopicity (b), hysteresis (c), and estimated deliquescent/ critical RH % (d) of
LFX-Acid 1:1 films
Moving on to the DVS results in figure 4.5, we can explore relative interactions
with environmental moisture of the film precipitates. In panel a), we can see an
example equilibrium sorption and desorption isotherms at 25 °C of the glutaric acidLFX film. From these isotherms, information to explore the film interactions with
moisture were extracted for comparison across all acids. The square symbols () are
the relative humidity (% RH) conditions at which the hygrosopicity (i.e. the extent
of water uptake) was compiled as representative low (30 %), medium (60 %), and
high (90 %) % RH conditions as displayed in panel b) for comparison. Hysteresis
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assessments, taken as the difference in moisture uptake between the sorption and
desorption isotherms, were recorded at 10% RH as well as the % RH which exhibited
the maximum difference for each acid film and is compiled in panel c). Lastly, an
estimated deliquescent point or critical RH % is recorded for the % RH condition at
which the water uptake increased rapidly with increasing humidity (identified by the
red triangle for an estimate of 70% for the glutaric acid film), which is presented for
comparison in panel d).
Per the hygroscopicity data, we can observe substantial differences in water uptake
by the acid used and also that most of the acids took up very large amounts of
moisture at 90% RH conditions. Notably, the malic acid film is very resistant to
moisture uptake at all conditions and exhibits behavior most similar to the pure LFX
film. This highlights malic acid as a leading contender to minimize water interactions
in the solid state, which may be robust to even very high water activity. If the 90%
condition is neglected as a properly manufactured and packaged drug product is not
expected to experience such conditions, then fumaric, adipic, pimelic. succinic, citric,
and glutaric acids all appears to be reasonably resistant to water uptake at 60% RH
or less. Glutaric acid does show a striking increase at higher RH which may imply
a high risk /lower robustness to varying RH conditions. Oxalic, maleic, and tartaric
demonstrate greater moisture uptake than the other acids at lower RH which may
increase LFX exposure to water. In panel c) we can observe the hysteresis results
where the LFX, malic, pimelic, adipic, fumaric, and succinic acid films demonstrate
the least difference between the soprtion/desorption isotherms. This implies that the
solid state forms of these acids may be resistant to change in the presence of moisture
regardless of moisture uptake, which is a good indication of physical stability such that
we might expect the precipitate form to stay consistent and predictable throughout a
range of humidity exposures. It is worth noting that those acids which had the lowest
hygroscopicity from panel a) also had the least hysteresis. In panel d) we can find the
estimate deliquescent or critical RH % for all acid films except for the LFX, adipic,
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malic, fumaric, and tartaric films which did not appear to exhibit a rapid change
in moisture uptake with increasing humidity. Those films which may deliquesce at
lower humidities are likely at the highest risk of extensive hydrolysis and expressing
sensitivity to variation in environmental moisture. Taken together, the malic acid
film demonstrates the most preferred solid-state behavior across all techniques due to
the confirmed crystal form by XRD, possible favorable interactions by DSC co-crystal
behavior, and lowest exhibited water interactions per DVS results.
We must also consider the physical and chemical acid properties that may govern
potential stabilizing interactions as captured in table 4.2. These include molecular
weight, melting temperature, acidity (i.e. pKas), solubility in both ethanol and water, hydrophobicity/philicity (per log P), the number of hydrogen bond donors and
acceptors (in total and by mass), topological polar surface area, crystalline density,
enthalpy, and entropy parameters. As we know that the API is better stabilized in
increasingly acidic media in the solution state, we likewise expect such behavior to
apply in the solid state as well. The acids with the lowest pKas, specifically oxalic,
maleic, and tartaric acids, would be expected to best reduce the solid-state pH to
reduce the hydrolysis rate. Furthermore, as the active site of hydrolysis is an strong
hydrogen-bond acceptor, it is anticipated that those acids with greater and stronger
hydrogen-bond donating (HBDs) groups will be best suited to stabilize LFX - those
acids with the most potential to accept strong hydrogen bonds are citric, tartaric and
malic acids.
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Table 4.2: Organic Acid Properties

[203, 222]

[221, 205]

[219, 220]

[217, 218]

[215, 216]

[213, 214, 209]

[212, 209]

[211, 205]

[210, 203]

[208, 209]

—

Sources

Hydrophobicity/philicity as explored by water solubility and log P can describe
the relative extent of interactions with water - more strongly hydrophobic materials
(low solubility, high log P) may allow the acid to repel moisture from the local environment of the API or in contrast, while more strongly hydrophilic materials (high
solubility, low log P) may bind moisture more tightly such that it is less available to
react with the drug. The most hydrophobic acids appear to be adipic, fumaric, and
pimelic acids while the more hydrophilic acids appears to be citric, malic, tartaric
and maleic. Glutaric, oxalic, and succinic acids appear to be more centered between
these extremes.
Additionally, ethanol solubility may help describe the propensity for phase separation during the precipitation process from the API and may dictate the relative
homogeneity between the API and acid. It is expected that having the API in close
proximity to the acid will be beneficial for reduction in the local environment solid
state pH. Notably, those acids which are the least soluble in water likewise appear to
be less soluble in ethanol. Based on these considerations from the physical-chemical
property data, it may be anticipated that oxalic, maleic, tartaric, citric and malic
would be top performers due to low pKas and multiple HBDs; provided that the
potential hydrophilicity is not detrimental.
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Degradation Rate Analysis

Figure 4.6: The change in hydrolysis product (LADP) amount relative to LFX by
HPLC area ratios for all ten acid formulations at 0.565 w/w % (1x) after two weeks
exposure to accelerated stability conditions (i.e. 40°C/75% RH. The top five performing acids (malic, oxalic, citric, tartaric, and maleic) were selected for additional
study.
Initial stability screening results conducted for two weeks at 25 °C/ 58% RH found
the top five performers to be the malic, oxalic, citric, tartaric and maleic acid formulations. These results align well with the solid state expectations in terms of favorable
API-acid interactions indicated per the previously discussed XRD and DSC results.
Interestingly, these acids are also those that exhibit more hydrophilic properties as
demonstrated in figure 4.5 and table 4.2; with the exception of very low moisture
interaction of malic acid per the DVS results. The continued stability studies, rate
constant, and projected shelf life results for the top five formulations can be found in
figure 4.7 and table 4.3, respectively. From these results, it is clearly observed that
the malic acid formulation consistently outperforms all other formulations regardless
of storage condition; while the citric acid formulation relative performance varies sub-
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stantially in comparison to the other acids. This also appears to highlight the greater
sensitivity of the citric acid formulations to changing humidity exposure.

(a) 0.565 w/w % (1x) acid amount with six weeks
exposure time at 25 °C/43 %RH storage conditions

(b) 0.565 w/w % (1x) acid amount with six weeks
exposure time at 25 °C/58 %RH storage conditions

(c) 0.565 w/w % (1x) acid amount with four weeks
exposure time at 40 °C/75 %RH storage conditions

(d) 5.654 w/w % (10x) acid amount with two weeks
exposure time at 40 °C/75 %RH storage conditions

Figure 4.7: Summary stability results for top five acids formulations at varying acid amounts
(0.565 w/w % - 1x (a,b,c), 5.654 w/w % - 10x (d)), exposure time (six (a,b), four (c), and
two (d) weeks) and storage conditions (25 °C/43 %RH (a), 25 °C/58 %RH (b), and 40 °C/75
%RH (c, d)). Malic acid is consistently the top performer at all conditions, while citric acid
varied the most with respect to humidity.

To quantitatively understand the effects of temperature and environmental moisture on the degradation rates, the data from the top 5 acids at the 1x acid amounts
were fit to the model described in equation 4.1, with the results listed in table 4.4.
Ideally, stability data would have been collected at more temperatures and stability
conditions (n≥5) to provide better parameter estimates and confidence intervals, but
there is still value in using the existing data to generate an understanding of the
underlying effects diving differences in stability performance. From the modified Arrhenius model, we would expect that reduced temperature and moisture sensitivity
would be expressed by large Ea values and smaller B values, and would be most
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favorable for drug product stability. The pre-exponential term is typically considered
temperature independent relative to the other parameters within the temperature
ranges explored in drug stability studies, and instead represents the relative entropic
favorability for the reaction to proceed.
Interestingly, oxalic acid had the greatest resistance to temperature and humidity
effects, but the high pre-exponential factor overrode these benefits relative to the malic
performance. This may be attributed to the small molecular weight of the acid which
implies greater mobility in the solid-state that allows greater frequency of favorable
collisions to occur. Alternatively, the smaller size of the acid may provide reduced
steric hindrance and/or greater access of water molecules to the active site of the
API to initiate the hydrolysis mechanism. In contrast, citric acid had the greatest
temperature and moisture sensitivity, but had the smallest pre-exponential factor.
This aligns with its larger molecular weight and greater number of sites available
for hydrogen-bonding which my restrict the mobility of moisture in the formulation
near the API. However, the enhanced sensitivity to moisture may be due to the
plasticization effects of sorbed moisture on amorphous solids, such that free volume
and molecular mobility is rapidly increased in the presence of increasing moisture
content. At low temperature and humidity conditions, citric acid may be the best
performing acid due to its order of magnitude or more lower A value, but it implies
poor robustness against varying environmental exposure which is not desired for a
drug product that may experience multiple such conditions across the shelf life and
particularly once the packaged product is open for patient use.
Malic acid was found to be the best candidate acid per its consistently lowest
degradation rates, with the median A value, 2nd highest Ea and B values respectively.
It is interesting that the malic acid formulation was found to be relatively high in
water sensitivity given that the opposite of these results were implied from the DVS
data. It is worth reiterating that the data fit to equation 4.1 is limited and may
help explain some of this discrepancy. However, even with the higher B value and
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at high relative humidities, the high Ea term helps to attenuate these effects. For
example, even at 100% RH conditions, the moisture contribution to the sum of the
malic acid exponential terms (i.e -Ea /RT + B ∗ RH), is equivalent to an Ea of 101.5
kJ/mol which is still larger (i.e higher net energy barrier for the reaction to overcome)
than the citric, maleic, and tartaric acid exponential sums at 0% RH (96.6, 98.9, and
94.9 kJ/mol, respectively). Likewise, the two orders of magnitude difference in the
pre-exponential factors for oxalic and malic is sufficient to explain how malic can be
more stable even with greater temperature and humidity sensitivity. These findings
demonstrates the greater importance of a high Ea and low A values in the mitigation
of the hydrolysis of LFX.
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Table 4.3: Initial degradation rate constants (k) for top five acid formulations
Acid

Amount

Condition

Rate +/- 95% CI

Shelf Life

—

w/w %

°C / % RH

(% LADP/LFX)/DAY

days

1x

25 / 43
25 / 58†
40 / 75

0.0224 +/- 0.0109
0.0596 +/- 0.1121
0.8915 +/- 0.2326

134
50
3

10x

40 / 75

0.1750 +/- 0.1175

17

1x

25 / 43†
25 / 58†
40 / 75†

0.1002 +/- 0.2140
0.1407 +/- 0.1178
1.3830 +/- 2.8741

30
21
2

10x

40 / 75

0.1436 +/- 0.0204

21

1x

25 / 43
25 / 58
40 / 75

0.0061 +/- 0.0180
0.0118 +/- 0.0089
0.1938 +/- 0.0432

492
254
15

10x

40 / 75

0.0519 +/- 0.0665

58

1x

25 / 43
25 / 58
40 / 75

0.0229 +/- 0.0091
0.0301 +/- 0.0080
0.3730 +/- 0.0643

131
100
8

10x

40 / 75

0.0679 +/- 0.1132

44

1x

25 / 43†
25 / 58†
40 / 75†

0.0720 +/- 0.1318
0.0996 +/- 0.0357
0.9019 +/- 3.1176

42
30
3

10x

40 / 75

0.1316 +/- 0.0551

23

Citric

Maleic

Malic

Oxalic

Tartaric

†

: Rate constants extracted from 2 order polynomial fit at t = 0 ;
otherwise linear fit used for all other conditions
nd

Table 4.4: Modified Arrhenius Factors for the top five acid formulations
Acid
—

A
%/day

Ea
kJ/mol

B
—

Citric
Maleic
Malic
Oxalic
Tartaric

1.87 ∗ 1014
8.20 ∗ 1015
5.35 ∗ 1015
9.82 ∗ 1017
1.22 ∗ 1015

96.6
98.9
107
114
94.9

0.0553
0.0223
0.0434
0.0183
0.0217

In addition to understanding the factors which drive hydrolysis rate, the other
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primary goal of this work is to identify an acceptable formulation for continued development that can be expected to meet the shelf life requirements of less than 3% LADP
formation over two years (730 days) when held at 25 °C / 60 %RH. A comparison of
the stability results for the citric and malic formulations are explored in greater detail
(table 4.5) to meet this target, as citric acid was used in the initial formulation and
malic acid is the clear leading acid from those explored in this study. Notably, the
malic acid formulation demonstrates expected shelf lives 3-5x greater (or conversely
degradation rates 3-5x smaller) than citric acid, though they are still well below the
target 730 days. However, this data is still encouraging for a multitude of reasons.
The higher 10x acid content is found to improve rate constants 3-5x under accelerated
stability conditions relative to the low acid contents. If similar improvement can be
translated to the long term stability conditions (i.e. 25 °C / 60 %RH), then we can
readily expect the malic formulation to meet the desired shelf life. These findings
also suggest that further increases in acid content may continue to increase stability
to provide additional assurances. Lastly and most importantly, these stability studies are conducted on open powder formulations that are not sealed in appropriate
packaging conditions or otherwise protected from environmental moisture. For example, tablets made from these formulations could be coated with a moisture protective
barrier and/or stored in a low moisture vapor diffusion packaging condition with desiccant to scavenge excess moisture - all of which would be expected to drastically
improve hydrolysis stability. As such, identifying a powder formulation under these
storage conditions that is able to improve stability from the reference formulation by
3-5 fold by the simple exchange of acid, and and additional 3-5 fold by increasing
the amount of acid - allowing for a potential 9-25 fold improvement overall, if these
effects are found to be additive.
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Table 4.5: Comparison of Citric and Malic Acid Formulations
Comparison of Citric vs. Malic Degradation Rates
Amount

Condition

p-value

k Ratios (CA/MA)

w/w %

°C / % RH

—

—

1x

25 / 43
25 / 58
40 / 75

0.0286
0.0133
0.0002

3.696 +/- 2.5806
5.046 +/- 1.1600
4.599 +/- 0.3666

10x

40 / 75

0.0074

3.371 +/- 0.3837

Comparison of 1x vs 10x w/w % Degradation Rates

4.5

Acid

Condition

p-value

k Ratios (1x/10x)

—

°C / % RH

—

—

Citric
Malic

40 / 75
40 / 75

0.0010
0.0011

5.093 +/- 0.4096
3.733 +/- 0.4230

Conclusions

In this chapter we have found that the citric acid formulation is likely to form an
amorphous phase with the drug when sprayed out of ethanol onto the granulation
powder bed, while all other acids resulted in various crystal forms. The prevalence
of co-crystal/salt formations appears likely with a number of the evaluated acids
per DSC and XRD results. The malic acid formulation clearly exhibited the most
beneficial water interactions per the DVS studies which is promising for the reduction
of hydrolysis reactions in particular. Overall, the solid-state characterization data
indicated that the malic acid formulation demonstrated the most favorable properties
for drug stability.
The initial screening stability study identified citric, maleic, malic, oxalic, and
tartaric acids as the top five contenders for further investigation. These top performing acids agreed well with the expectations from the solid state characterization and
acid physical-chemical property data, where greater acidity and hydrophilicity were
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correlated with improved performance. These top acid formulations were evaluated
at multiple temperature and humidity conditions for the determination of reaction
rate parameters from the modified Arrhenius equation, such as the pre-exponential
factor A, energy of activation Ea , and humidity factor B. Of these, it was found that
the most important outcomes for better stability performance were a large Ea with a
small A, which can make the humidity factor less pertinent. Citric acid was found to
have the greatest moisture sensitivity which is consistent with plasticization effects
that would be expected of amorphous forms.
The malic acid formulation at the higher acid content has been identified as the
best acid choice for the stabilization of this LFX controlled-release tablet with a
potentially improved shelf life of 9-25 fold that of the reference citric formulation, with
greater resistance to temperature and humidity effects. Overall, the data consistently
highlights malic acid as the best stabilizing material for LFX against hydrolysis and
offers promised of the continued successful development of a controlled release drug
product.
4.6

Future Work

Additional hydrolysis mitigation strategies
Protective coatings on tablets or capsules can add an additional moisture barrier
such that hydrolysis can be slowed by reducing the rate of moisture accumulation
in the drug product [224]. Investigations of coating types, amounts/thickness, and
processing methods could further mitigate the formation of the LADP hydrolysis
product. Packaging considerations such as foil pouches, blister packs, and/or HDPE
(high density polyethylene) bottles inhibit moisture uptake in the local environment
of the drug product to help reduce the hydrolysis rate by minim zing the relative
humidity. Adding silicon dioxide desiccant is also frequently utilized as a moisture
scavenger to reduce relative humidity. There are many additional approaches that
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can be utilzied in addition to acid optimization to improve the hydrolytic stability of
LFX.

Copyright© Matthew Kyle Defrese, 2021.
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